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Vaccine Mediated Immunity To Malaria
Abstract
Malaria infects millions of people every year, and despite recent advances in controlling disease spread, it
remains a global health concern. Decades of research into both naturally acquired and vaccine mediated
immunity have given a broad range of correlates of protection. RTS,S, the only licensed anti-malarial
vaccine, has implicated antibodies against the circumsporozoite protein (CSP) as a key correlate. Not to
be discounted, CD8+ T cells targeting liver-stage (LS) antigens were associated with protection in
attenuated sporozoite vaccination. Clearly there is no panacea for malarial immunity, and a broad range
of responses against multiple antigens is crucial. In this work we develop novel synthetic DNA vaccines
targeting antigens in multiple Plasmodium pre-erythrocytic life cycle stages, and evaluate the immunity
elicited by each in the context of murine models of malaria. To further evaluate protection mediated by
Liver stage antigens, we focused on the exported pre-erythrocytic proteins EXP1, PFN, EXP2, ICP, TMP21,
and UIS3. SynDNA antigen cocktails were tested with and without the molecular adjuvant plasmid IL-33.
Immunized animals developed robust T cell responses including induction of antigen-specific liverlocalized CD8+ T cells, which were enhanced by the co-delivery of plasmid IL-33. In total, 100% of mice in
adjuvanted groups and 71%–88% in non-adjuvanted groups were protected from disease following
Plasmodium yoelii challenge. To further evaluate protection mediated by sporozoite antigens, five
synDNA vaccines encoding variations of CSP were designed and studied: 3D7, GPI1, ΔGPI, TM, and DD2.
ΔGPI generated the most robust immunity, and was the most efficacious in an IV sporozoite challenge.
We then compared the immunity generated by ΔGPI vs synDNA mimics for two leading malaria vaccine
candidates (RTS,S and R21). They demonstrated similar anti-CSP antibody responses, however ΔGPI
induced a more focused T cell response. In an infectious mosquito challenge all three of these constructs
generated potent inhibition of liver stage infection, with ΔGPI appearing to also provide the best sterilizing
immunity from blood stage parasitemia. Together these studies demonstrated that synDNA vaccines
encoding malaria immunogens can provide substantial protection from disease, and highlighted the
importance of targeting the pre-erythrocytic life cycle stages to combat malaria.
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ABSTRACT
VACCINE MEDIATED IMMUNITY TO MALARIA
Sophia M. Reeder
David B. Weiner

Malaria infects millions of people every year, and despite recent advances in controlling
disease spread, it remains a global health concern. Decades of research into both naturally
acquired and vaccine mediated immunity have given a broad range of correlates of protection.
RTS,S, the only licensed anti-malarial vaccine, has implicated antibodies against the
circumsporozoite protein (CSP) as a key correlate. Not to be discounted, CD8+ T cells targeting
liver-stage (LS) antigens were associated with protection in attenuated sporozoite vaccination.
Clearly there is no panacea for malarial immunity, and a broad range of responses against
multiple antigens is crucial. In this work we develop novel synthetic DNA vaccines targeting
antigens in multiple Plasmodium pre-erythrocytic life cycle stages, and evaluate the immunity
elicited by each in the context of murine models of malaria. To further evaluate protection
mediated by Liver stage antigens, we focused on the exported pre-erythrocytic proteins EXP1,
PFN, EXP2, ICP, TMP21, and UIS3. SynDNA antigen cocktails were tested with and without the
molecular adjuvant plasmid IL-33. Immunized animals developed robust T cell responses
including induction of antigen-specific liver-localized CD8+ T cells, which were enhanced by the
co-delivery of plasmid IL-33. In total, 100% of mice in adjuvanted groups and 71%–88% in nonadjuvanted groups were protected from disease following Plasmodium yoelii challenge. To further
evaluate protection mediated by sporozoite antigens, five synDNA vaccines encoding variations
of CSP were designed and studied: 3D7, GPI1, ΔGPI, TM, and DD2. ΔGPI generated the most
robust immunity, and was the most efficacious in an IV sporozoite challenge. We then compared
the immunity generated by ΔGPI vs synDNA mimics for two leading malaria vaccine candidates
(RTS,S and R21). They demonstrated similar anti-CSP antibody responses, however ΔGPI
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induced a more focused T cell response. In an infectious mosquito challenge all three of these
constructs generated potent inhibition of liver stage infection, with ΔGPI appearing to also provide
the best sterilizing immunity from blood stage parasitemia. Together these studies demonstrated
that synDNA vaccines encoding malaria immunogens can provide substantial protection from
disease, and highlighted the importance of targeting the pre-erythrocytic life cycle stages to
combat malaria.
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CHAPTER 1: INTRODUCTION
1.1: A brief history of malaria

Malaria has haunted humanity for nearly as long as we have been keeping
records. References to a malarial illness in ancient Chinese documents as far back as
2700 BC1. A similar malady is described in clay tablets from Mesopotamia in 2000 BC, in
Egyptian papyri from 1570 BC, and in Hindu texts from as far back as the 6th century
BC1,2. Of course, these early and somewhat vague accounts should be viewed with
some level of skepticism. We find ourselves on more trustworthy ground with the Early
Greeks (including Homer in 850 BC, Empedocles of Agrigentum in 550 BC, and
Hippocrates in 400 BC) who were familiar with the distinctive malarial fevers and
enlarged spleens seen in patients living on swampy, mosquito ridden land1,3.
For well over 2500 years, it was believed that malarial fevers were caused by
miasmas rising from swamps. This concept was so pervasive that it is widely believed
that the term ‘malaria’ comes from the Italian “mal’aria” which translates to ‘bad air’. It
was not until the discovery of bacteria by Antonie van Leeuwenhoek in 1676, and the
subsequent development of the germ theory of disease by Louis Pasteur and Robert
Koch in 1878-79 that the field turned to searching for a microorganism as an explanation
for malaria. However, it would be many years before the true cause and mechanism of
infection was uncovered.
By 1879, in congruence with the discoveries of Pasteur and Koch, the miasma
theory was falling out of favor. The two prevailing theories which replaced it, both based
on the assumption a microorganism was the culprit, were whether the microorganisms
1

were transmitted 1) by air and inhalation, or 2) by water and ingestion. It should be noted
that at this time the field was still searching for a bacterial cause rather than a protozoan
one, even so far as the discovery and naming of a novel bacterium, Bacillus malariae,
which was implicated as the causative agent of malaria by noted German scientist
Theodor Albrecht Edwin Klebs, who had also been the first to observe the bacterial
agents for typhoid and diphtheria4.
An unexpected challenger rose to dispute the bacterial hypothesis. The French
Army officer Charles Louis Alphonse Laveran was posted in Algeria when he began his
studies on malaria. Having noted that his malarial patients often exhibited strange
pigmentation in their enlarged spleens, he adopted the strategy of ‘follow the pigment’
and began to search for pigment in the blood of his malarial patients. He observed
several different forms of erythrocytic organisms in the blood, with varying levels of
pigmentation. Based on his observations he suggested a course of events for the
development of these organisms, which culminated in the bursting of red blood cells,
coinciding with the cyclical fevers characteristic of malaria. He further noted that quinine,
an anti-malarial commonly used by the colonialist European military officers in Africa,
removed these organisms from the blood. Laveran named this parasitic protozoan
Oscillaria malariae and presented his findings to the French Academy of Medical
Sciences in 18805. He was largely scoffed at by the eminent scientists of the day, who
did not believe he was observing anything more than disintegrating red blood cells.
Despite this inhospitable reception, Laveran continued with his research and over time
convinced key members of the field of the verity of his observations6, and was awarded
with the Nobel Prize for Medicine in 1907, twenty seven years after his initial, derided
presentation1,7.
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Laveran’s work demonstrated that the parasitic protozoan was the
microorganism responsible for malaria, however the mystery of how humans came to be
infected with the Plasmodium parasites continued. Centuries of circumstantial evidence
accumulated, and in 1883 the American physician Albert King assembled and published
the evidence that would come to be known as the mosquito-malaria doctrine8. Patrick
Manson, who had previously demonstrated the transmission via mosquitoes of another
parasitic organism, the filarial worms which cause lymphatic filariasis9, counseled his
student Ronald Ross to search for a mosquito vector for malaria10. While Ross was
posted in India, he followed Laveran’s dictate to “follow the pigment” and examined
several thousand mosquitoes from endemic areas. Eventually he observed the formation
of pigmented bodies (which he named ‘spores’) on the stomach wall of a mosquito which
had been experimentally fed on an infected patient. Further, he noted that after feeding
on an infectious patient, the far more common ‘grey’ culicine mosquitoes never
contained pigmented bodies, whereas the ’dapple-winged’ anopheline mosquitoes
contained pigmented bodies which ruptured releasing ‘rods’ which invaded mosquito
salivary glands11. This was a crucial breakthrough demonstrating the presence of human
malaria parasites in mosquitoes12.
It had previously been hypothesized by William MacCallum that Plasmodium has
a sexual stage of development, after he observed the combination of male and female
gametes to form a zygote in the blood of crows infected with Haemoproeus columbae, a
hematozoan closely related to malaria parasites13. Knowing of MacCallum’s work in
birds, combined with his own work, Ross concluded that Anopheles mosquitoes fed on
infected mammals, took up the male and female gametocytes of the Plasmodium
parasite in their blood meal, which then fertilized within the mosquitoes gut, and
3

developed into the ‘spores’ which he had observed, within which rod-like structures were
produced, which invaded the mosquitoes salivary gland and were subsequently injected
into a new mammalian host when the infected mosquito fed11. Further evidence
implicating mosquitoes as the vector for malaria transmission came from a seminal study
by Italian malariologist Giovanni Battista Grassi. Grassi sent volunteers to the Capaccio
plains, a malarious region in Italy, and protected a fraction of them from mosquito bites
from dawn to dusk. Of the 112 volunteers who were protected from mosquito bites, only
5 developed malaria. In contrast, all 415 of the unprotected volunteers contracted the
disease14. Not only did this study cement the role of mosquitoes as the vector for
Plasmodium scientifically, but it also set the precedent for controlling malaria by reducing
contact with infected mosquitoes, through methods such as screening and mosquitoproofing homes which are still commonly employed today.
Scientists now understood that malaria was caused by a species of the parasitic
protozoa Plasmodium, that it infected red blood cells, had a sexual stage of development
in the blood, and was transmitted by mosquitoes. However, the understanding of the
lifecycle of malaria in humans remained incomplete until the 1930s. The parasites could
not be observed in the blood during the first ~10 days after infection, and it was unknown
where in the body the parasites developed. Grassi and colleagues had begun to
investigate the possibility of development in other cells types, but these endeavors were
abandoned following a study by well-respected German scientist Fritz Schaudinn in
1903 which mistakenly described the direct invasion of red blood cells by the infective
sporozoites of Plasmodium vivax15. Despite the field’s inability to confirm these
observations, Schaudinn’s hypothesis dominated scientific opinion for over forty years,
and is now referred to as Schaudinn’s fallacy. The question of exoerythrocytic parasite
4

development was first properly addressed in avian rather than mammalian malaria16.
MacCallum, a noted avian malariologist who had also been the first to postulate a sexual
stage of development for Plasmodium, observed developmental phases of Plasmodium
relictum in the livers and spleens of infected birds13. However it was not until 1937 that
Sydney James and Parr Tate conclusively demonstrated that in Plasmodium
gallinaceum infections in chickens there was a phase of multiplication between the
injection of sporozoites, and the appearance of parasites in the blood, and that this
occurred in cells of the reticuloendothelial system17. There was a delay of another ten
years until the same conclusion could be reached in primate Plasmodium infections; in
1947 Henry Shortt and Cyril Garnham showed that a phase of division in the liver
preceded the development of parasites in the blood18–20. Shortly after, Shortt, Garnham,
and colleagues found exoerythrocytic forms of Plasmodium vivax21, Plasmodium
falciparum22, and Plasmodium ovale23 in human volunteers. The only remaining mystery
in the life cycle of Plasmodium parasites was the source of the long pre-patent periods
and the appearance and reappearance of parasites in blood seen in some strains of
Plasmodium vivax. This question was answered by Wojciech Krotoski in 1982 while he
was working with Garnham’s team, and discovered the dormant hypnozoite stage of
Plasmodium vivax24.
After thousands of years of living with malaria, an unknown French scientist with
a rudimentary microscope noticed organisms in his malaria patient samples, and 122
years later the complete genome for Plasmodium falciparum was published in 200225,26.
There remain many questions to be answered concerning the basic biology of
Plasmodium, and malaria remains an immense global health burden. New technologies
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will allow us to address these questions in innovative and integrative ways as we move
forward into the future from the history of malaria.

1.2: The basic biology of malaria parasites
Malaria continues to cause disease in 229 million humans annually with a death
toll of approximately 409,000 per year27. Malaria infections are caused by the plasmodial
species of parasite; six species of Plasmodium are infectious to humans: Plasmodium
falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale curtisi,
Plasmodium ovale wallikeri, and Plasmodium knowlesi. Plasmodium falciparum is
responsible for the majority of deaths caused by malaria, and thus is often considered
the most important for human health. Although the focus on Plasmodium falciparum is
certainly appropriate, Plasmodium vivax should not be discounted, as it has recently
been shown to be a comparable cause of severe disease in Southeast Asia, and it has
been increasingly argued that Plasmodium vivax is underestimated28. Plasmodium
malariae, Plasmodium ovale curtisi, and Plasmodium ovale wallikeri are much less
common causes of severe disease29. Plasmodium knowlesi was previously considered
to be a primate-infecting parasite, however it is now known that Plasmodium knowlesi is
a zoonosis involving macaque and leaf monkeys as reservoir hosts with Anopheles
mosquitos as the vectors, in Malaysia and elsewhere in Southeast Asia30,31. Further,
advances in PCR identification have revealed that many infections previously attributed
to Plasmodium malariae were in fact caused by Plasmodium knowlesi31.
Like many other apicomplexan parasites, Plasmodium parasites have a complex
life cycle, with stages in both vertebrate and invertebrate hosts (Figure 1.1). As Ronald
6

Ross concluded many years ago, Plasmodium sporozoites are injected into the dermis
during a blood meal by a female Anopheles mosquito12. The sporozoites then use gliding
motility to reach and penetrate a blood vessel, allowing them to enter the blood stream32.
Many sporozoites are destroyed in the skin and drained to the lymphatics29. Those that
successfully exit the dermis and access the blood stream quickly access the liver via
traversal. The sporozoites cross the sinusoidal barrier comprising endothelial cells and
macrophage-like kupffer cells33, their traversal of these cells is mediated by the
formation of a transient vacuole34. When sporozoites are injected into the dermis they
are in ‘migratory mode’ and upon interaction with hepatocytes convert to ‘invasive
mode’. One molecular signal for this transition is sporozoite recognition of hepatocytes
through binding highly sulfated proteoglycans, activating calcium dependent protein
kinase 6 (CPK6)35, which in turn activates the processing of the circumsporozoite
surface protein (CSP) which coats the surface of the parasite and is crucial for invasion36
(see chapter 3 for CSP specific background).
Once the sporozoite has successfully invaded the hepatocyte, the sporozoite
transforms to a liver stage or exo-erythrocytic form (EEF). The liver stage (LS) parasite
is separated from the infected hepatocyte by a selective parasitophorous vacuolar
membrane (PVM) of host hepatocyte plasma membrane origin32,37. The growing LS
parasite acquires nutrients from its host hepatocyte and at the same time prevents its
apoptosis38–41. This stage of development culminates in the release of up to 40,000
merozoites/hepatocyte into the blood stream by budding of parasite filled vesicles called
merosomes42. See chapter 2 for in-depth liver stage background.
Free merozoites then invade erythrocytes in a multistep process including 1)
pre-invasion, 2) active invasion, and 3) echinocytosis, all of which is complete within two
7

minutes43. The pre-invasion step involves receptor-ligand interaction between the
merozoite and the erythrocyte, which results in parasite actomyosin motor driven
deformation of the host cell43. Following this, the irreversible attachment of merozoites to
erythrocytes occurs via formation of a tight junction formed between parasite derived
proteins: AMA1 and the RON complex. The RON complex is deposited in the
erythrocyte, with RON2 spanning the host membrane and binding to AMA1 on the
merozoite surface44. Lipid-rich rhoptry contents form the parasitophorous vacuole
membrane (PVM) as the merozoite is propelled into the erythrocyte using force
generated by the parasite actomyosin motor45. Finally, after the active invasion phase is
complete, fusion of membranes at the posterior end of the merozoite seals the parasite
within the PVM within the erythrocyte. Echinocytosis follows, and causes the erythrocyte
to shrink and form spiky protrusions43.
Over the next two days, schizogony results in 16-32 new merozoites, which
egress when developed, destroying the host erythrocyte in the process as they are
released to access new host cells for invasion46–48. This explosive release of merozoites
coupled with the rupture of host erythrocytes are responsible for the characteristic fevers
and pathophysiology associated with malaria infections. Infected erythrocytes undergo
extensive modification, which allows the intracellular parasite to grow and hide from host
immune responses49. During these rounds of schizogony, a number of parasites
transition to sexual development, to form male and female gametocytes. The
gametocytes are taken up by a female Anopheles mosquito during a blood meal, receive
activation signals including change in temperature and pH, and rapidly convert to fertile
gametes50,51. After fertilization, the zygote further converts into the motile and invasive
ookinete stage. Once the ookinetes are formed, they exit the gut lumen by traversing
8

through the mosquito midgut epithelial cell layer, before depositing on the basal site of
the epithelium and converting once more into sessile oocysts, which undergo sporogonic
replication37. Over the course of the next two weeks, this results in infectious sporozoites
which migrate to the mosquito salivary glands and are subsequently injected into the
human dermis during the next blood meal, and the cycle begins anew52,53.
1.3: Naturally acquired immunity to malaria
The nature of malaria infections has made the task of identifying correlates of
protection a difficult one. Many cohort studies have attempted to address this question,
however small effect sizes and the polymorphic nature of immunogenic parasite
proteins54, combined with the inherent difficulty of addressing heterogeneity of malaria
exposure (age, local transmission pressure, maintenance of baseline immune responses
throughout the study or lack thereof)55 have made the identification of true correlates of
protection ambiguous at best. Further complicating this search, unlike many pathogens
which elicit a highly potent, long-lived immune response, human naturally acquired
immunity to malaria is less potent and is short lived56; true immunity to infection is rare,
though immunity to disease does develop naturally over time and repeated exposure57.
This difference between immunity to disease vs immunity to parasites is an important
consideration. There is huge variability in parasite strains, and immunity is acquired to
each isolate that is survived, giving ‘strain-specific immunity’. Over time, immunity builds,
due to the acquisition of a repertoire of responses to many different isolates, and/or the
development of a cross-protective response to shared antigenic targets29.
Much of naturally acquired immunity targets the asexual blood stage, and is
antibody mediated. Blood stage parasitemia is associated with the clinical symptoms of
9

malaria infection, as the cycles of rupturing erythrocytes causes an upregulation of proinflammatory cytokines. Antibodies to blood stage antigens are associated with clinical
immunity in endemic areas58–60. Antibodies are generated either against the free
merozoite, or against the infected erythrocyte. Antibodies against the free merozoite
prior to invasion could block the ability of the parasite to enter the erythrocyte, or lead to
cell-mediated destruction of the parasite via mechanisms including opsonophagocytosis,
antibody dependent cellular inhibition (ADCI), or neutrophil mediated killing29. Antibodies
against the infected erythrocyte may also recognize the highly modified host cell surface,
triggering cell mediated ingestion or killing, or blocking cyto-adhesion of the infected
erythrocyte to endothelial cells, making it susceptible to splenic removal61.
Antibodies against parasite proteins from developmental stages other than the
asexual blood stage have also been identified as being important. The Glutamate-rich
protein (GLURP) is expressed in all the developmental stages of Plasmodium falciparum
in humans62. The presence of antibodies to GLURP is associated with protection from
clinical disease63,64, and antibody-dependent cellular inhibition is hypothesized to be an
important element in GLURP-specific protective immunity64. Antibodies against Liverstage antigen 1 (LSA-1) are also associated with protection against clinical malaria63.
LSA-1 is produced shortly after hepatocyte invasion and accumulates within the PVM
surrounding the mass of developing merozoites65. LSA-1 plays a critical role during latestage liver schizogony, and is thus important in the parasite transition from liver to blood
stages66. Antibodies against the circumsporozoite protein (CSP), a key surface protein of
the sporozoite stage of the parasite, have long been identified as being of importance for
protection from clinical malaria (see chapter 3 for further information on CSP).
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A key caveat when considering our knowledge concerning the naturally acquired
correlates of protection is the limitations on the types of samples that can be collected
from human patients. If the immunological information cannot be gleaned from a blood
sample, either through sera analysis or through analysis of cryo-preserved peripheral
blood mononuclear cells (PBMCs), it will be difficult to assess in a human population.
This leaves out tissue resident populations of cells, which vaccine studies have indicated
are of importance (see below). Though the study of cohorts of patience in endemic areas
for naturally acquired immunity has been enlightening, many lessons about anti-malarial
immunity have also been learned from decades of vaccine work.
1.4: Anti-malaria vaccines- lessons learned
There are three main avenues that have been explored for anti-malarial
vaccines. These are 1) pre-erythrocytic vaccines, which aim to prevent malaria by
stopping infection before it reaches the symptomatic blood stage, 2) asexual blood stage
vaccines, which will be important for controlling morbidity and mortality, and 3) sexual
blood stage vaccines, which have the potential to interrupt the transmission cycle, but do
not have direct effect on an already established infection in the vaccinee.
The goal of pre-erythrocytic vaccines is to inhibit hepatocyte infections and
hepatic parasite development, which will in turn limit erythrocyte invasion and
symptomatic infection. Mechanisms of protection for vaccines targeting these
developmental stages include antibody responses which prevent sporozoites from
invading hepatocytes, and cytotoxic T cells which destroy infected liver cells57. By far the
most notable anti-sporozoite vaccine is RTS,S/AS01. As for anti-liver stage vaccines,
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attenuated whole sporozoite vaccines take center stage, though alternative vaccines
including those using a prime and trap strategy have also been making headway.
RTS,S/AS01 (RTS,S), one of the longest studied candidate vaccines (developed
by GSK over decades) is focused on generating immunity to CSP, the circumsporozoite
protein of Plasmodium falciparum (Pf). RTS,S is a recombinant protein-based vaccine
comprised of a fragment of CSP containing a section of the repeat region, and the T cell
epitopes of the c-terminus attached to the Hepatitis B surface antigen protein, and
delivered with additional HbsAg to encourage the formation of virus-like-particles in
yeast, which are then harvested and administered with an adjuvant to humans to
generate a T cell and antibody response. This is the only vaccine to show significant
reduction in malaria in young children living in endemic regions. A phase 3 trial which
spanned 5 years demonstrated that children aged 5-17 months who received 4 doses of
RTS,S had a 39% reduction in malaria cases, and a 29% reduction in severe malaria
cases over 4 years of follow-up67. After positive recommendations by WHO advisory
boards, three countries, Ghana, Kenya, and Malawi began introducing RTS,S in 201927.
In the coming years, the Malaria Vaccine Implementation Programme (MVIP) will assess
the feasibility of administering the recommended 4 doses of the vaccine in children, the
potential role in reducing childhood death, and the safety of RTS,S in the context of
routine use68 as well as in specific important subpopulations.
An important recent advance in pre-erythrocytic malaria vaccines is the
development of a novel polyvalent immunogen R21, a recent anti-malaria vaccine
candidate, which builds on the knowledge gained from RTS,S. In contrast to RTS,S, R21
delivers a higher ratio of CSP to the Hepatitis B surface antigen (HBVsAg), which is in a
1 to 1 ratio as opposed to the 1 to 4 ratio of RTS,S5. Thus far R21 has proven to be well
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tolerated and immunogenic in early trials, as well as protective in a controlled human
malaria infection study (CHMI)69,70. The correlates of immunity which have emerged from
these malaria vaccines support the importance of anti-CSP antibodies primarily but also
suggest a role for T cells for imparting protection from Plasmodium infection67,69–74. The
role of anti-Plasmodium T cells in vaccination has been highlighted by attenuated
sporozoite vaccines75.
The only vaccination method that has led to long lasting complete sterile
protection against malaria parasite challenges in animals and in controlled human
malaria infection (CHMI) is immunization with live irradiation-attenuated sporozoites76,77.
Field studies in Burkina Faso, Mali, Kenya, Gabon, and Tanzania are currently following
up on this approach78. While these studies are important for the efforts to develop an
effective malaria vaccine, attenuation by irradiation is not easily standardized for human
use. Over-irradiated sporozoites confer little protection while under-irradiation provides
risk for breakthrough infections. More recently, attenuation of sporozoites was conducted
by targeted deletion of genes that encode LS essential proteins in the mouse model, or
by delivery of whole-sporozoites concurrently with chemoprophylaxis. In all attenuation
methods, Plasmodium sporozoites invade hepatocytes within vacuoles, then cease
growth and do not cause Plasmodium infection of the blood32,37,79,80. The protection
conferred by attenuated sporozoites was confirmed to be mainly mediated by CD8+ T
cells targeting LS antigens and not by antigens presented on the surface of migrating
sporozoites81–85. Recent studies pointed out that when compared to attenuated strains
that cease their LS development early, attenuated strains that grow longer in
hepatocytes before ceasing growth led to more significant protective immune
responses81. This indicated that significant exposure to LS antigens can enhance
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vaccine effectiveness. Further, liver-associated T cells have been implicated in antimalarial immunity following irradiated sporozoite vaccination86–88. When T cells lack
CXCR6, a cell surface marker highly expressed by liver-infiltrating CD8 T cells, there is a
reduction of liver-associated89 memory and sporozoite immunity86. It has been
established that CD8 tissue resident memory T cells are essential for protection against
LS malaria following vaccination87. Therefore, LS proteins are also important candidates
for inducing protective CD8+ T cell responses in the attenuated sporozoite model.
Despite the evident potential of live attenuated parasite models as vaccines, the
feasibility and large-scale application of live attenuated sporozoites that must be
produced aseptically in mosquitoes in high amounts is still in development90.
In contrast to pre-erythrocytic vaccines, the objective for anti-asexual blood stage
vaccines is to mimic the observed naturally acquired immunity that people living with
repeated malaria exposure in endemic regions develop. These patients achieve a state
in which their immune systems control erythrocyte invasion to some extent, resulting in
fewer disease symptoms or entirely asymptomatic infections91,92. This class of vaccine is
designed to elicit immune responses that will block/limit merozoite invasion of
erythrocytes, and prevent rapid replication of merozoites by targeting merozoite surface
protein (MSP) family members, apical membrane antigen 1
(AMA-1), and the reticulocyte homolog (Rh) proteins93–96. Alternatively, blood stage
vaccines may target parasite antigens which are embedded in the infected erythrocyte
membranes, such as PfEMP197. A common challenge for blood stage antigens, is that
while they are usually highly immunogenic, they are also highly polymorphic, so elicit
antigen and strain specific responses93,94. In contrast, antigens such as Rh which are
highly conserved95,96 tend to be less immunogenic98.
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The final class of anti-malaria vaccines are anti-sexual blood stage vaccines,
also known as transmission blocking vaccines, or TBVs. TBVs are designed to interrupt
the transmission of parasites between humans and the mosquito vector, by exploiting
host immune responses to parasite proteins, including both pre-fertilization and postfertilization antigens. These host immune responses against sexual stage parasites are
able to reduce the infectivity of the parasite, thus decreasing malaria transmission99,100.
However, a key caveat for TBVs, which are known as the ‘altruistic vaccine’ is that they
provide no immunity from disease for the vaccinee. For this reason, TBVs will likely be
best utilized as a component of a multi-antigen vaccine targeting multiple stages of
parasite development.
By themselves, none of the vaccination methods laid out above have been able
to achieve high-level, durable, cross-strain protection from malaria. In order to pursue
the goal of malaria elimination, radical new tools must be developed.
1.5: Advances in Vaccinology and their potential for combatting complex
pathogens
Since the work of Edward Jenner in 1796, the field of vaccinology has continually
evolved. Jenner noticed that inoculation with pus from cowpox lesions conferred
protection from smallpox infections101, and this landmark discovery paved the way for
vaccines, eventually resulting in the eradication of smallpox in 1979 following a global
vaccine administration program102. Jenner’s work was later refined by Louis Pasteur,
who was the first to attenuate viruses for use as vaccines. Although Jenner is often
lauded as the founder of vaccinology, it was Pasteur who established the basis of
vaccinology, i.e., the principle of inoculation, inactivation, and administration of diseasecausing pathogens. Pasteur’s principles allowed for the development of so-called “1st
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generation” vaccines, based on whole microorganisms which had been killed or
otherwise attenuated; this family of vaccines includes those against the plague,
pertussis, and smallpox, and the BCG vaccine for tuberculosis103,104. In the second half
of the twentieth century, improvements in mammalian cell culture technology enabled
the development of live attenuated “2nd generation” vaccines such as those for polio,
measles, rubella, mumps, and varicella. As a result, many of humanity’s greatest
infectious disease scourges have been greatly reduced, and polio has been nearly
eradicated105. It is without question that traditionally developed vaccines have changed
the landscape of public health, having prevented more than 700 million incidences of
disease and more than 150 million deaths in the past century106. That said, conventional
methods of vaccine design and development have limitations. First and second
generation vaccines have been unable to provide protection from pathogens with
antigenic hypervariability, such as HIV or HCV, or from pathogens with an intracellular
phase which cause infections that are partially or primarily controlled by T cells, such as
tuberculosis or malaria107. Antigenic polysaccharides, which primarily produce a B cell
dependent immune response, are covalently linked to carrier proteins, thereby providing
helper T cell activation. These glycoconjugate vaccines induced a stronger antibody
response, and thus increased their protective efficacy. Progress in molecular biology led
to the further development of this class of vaccines, in which purified recombinant
protein antigens are made to form a virus-like-particle (VLP)108.
Decades of research on vaccine candidates for malaria, as well as countless
studies interrogating the parasite’s basic biology and epidemiology have gleaned
valuable information. However, leveraging recent advances in bioinformatics, systems
biology, and non-traditional vaccinology has the potential to transform the field of malaria
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vaccines. Reverse vaccinology allows teams to have access to the entire repertoire of
pathogen proteins by sequencing and analysis, which can enable comparisons of
conserved sequences shared among pathogen strains within the same species109.
Advances in structural vaccinology have given us an improved understanding of the
native structures of biological macromolecules, and how changes in their structure affect
their function. This can in turn assist the identification of suitable epitopes.
Traditional vaccine design has relied on strategies like protein subunit vaccines
and weakened or killed versions of the pathogen in question. These techniques, while
valuable, have not yielded a high-efficacy malaria vaccine with durable cross-strain
protection. Advances in vaccinology, notably in the vaccine platforms of nucleic acid
vaccines and nanoparticle vaccines could be a solution. Synthetic nucleic acid vaccines
combine the advantages and high immunogenicity of in situ expression with the high
safety of subunit vaccines. Additionally, nucleic acid vaccines do not have potential
complications from pre-existing vector immunity as in the case of virally vectored
vaccines. Of key importance for infectious diseases of global health relevance like
malaria, nucleic-acid vaccines also have the potential to be produced simply and
inexpensively108. Among nucleic acid vaccines, both RNA and DNA vaccines must be
discussed.
RNA vaccines, which are based on mRNA or RNA replicons, have some
advantages and some disadvantages over DNA. RNA vaccines are active in the
cytoplasm and do not require delivery to the nucleus, however RNA vaccines are also
more susceptible to degradation and thus require additional stabilizing technology110.
mRNA vaccines are enjoying a rise in popularity; while the proof of concept for RNA
vaccines in humans was achieved in cancer vaccines years ago111–113, the advent of
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SARS-CoV-2 and the rapid response of Moderna and Pfizer/BioNTech resulting in the
first FDA approved SARS-CoV-2 vaccines both being mRNA vaccines114,115 will surely
result in a surge in mRNA vaccines in the years to come.
DNA vaccines held much of the focus in the nucleic acid vaccine field for many
years, and have been shown to be potent and efficacious in a wide variety of animal
species; this work has resulted in several licensed veterinary products116–119.
Initial studies of DNA vaccines in humans showed less than impressive
immunogenicity120, however recent advances in improved delivery through the use of
electroporation121, or through coadministration of immunostimulatory cytokines as
molecular adjuvants are overcoming these limitations122,123. Of note the low initial
immunogenicity was likely tied to lower levels of DNA expression in the early years of
DNA vaccine development, however innovative delivery methods such as jet delivery,
gene gun delivery, nanoparticle delivery, and others have demonstrated increased DNA
uptake in vivo124. With these innovations has come pre-clinical and clinical success
stories for DNA vaccines; multiple studies have now reported that synDNA vaccines
generate robust cellular and humoral immune responses against pathogens, with impact
in challenge model systems, as well as demonstrating a remarkable safety profile in the
clinic125–128.
Adaptive electroporation (EP), a technique which controls the energy delivered
during in vivo EP, increases the initial uptake pf plasmid by local cells approximately
500x over classical needle and syringe delivery129 . Following injection, plasmid DNA is
taken up by local cells at the site of injection, where the DNA is transcribed into mRNA
and translated into the antigen of interest intracellularly. In addition to the local myocytes
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which have become antigen factories, locally transfected antigen presenting cells
(APCs) can directly traffic to the regional lymph node, which is critical to initiating the
immune response130,131. Translated antigen can also be shed exogenously, and picked
up by APCs for subsequent cross presentation. Shed exogenous soluble antigen can
also drain to the regional lymph node, allowing for the engagement of B-cell immunity132.
Thus, local tissue at the site of injection becomes a sustained source of antigen, allowing
for presentation of antigen on major histocompatibility complex I (MHC-I) or MHC-II
molecules for re-expansion of lymph node primed CD8+ or CD4+ cells respectively133.
DNA vaccines also have potential as part of a heterologous prime-boost routine,
whereby DNA vaccines can effectively prime B- and T-cell responses (Figure 1.2).
Heterologous prime-boost vaccine strategies generally use either a viral vector or a DNA
vaccine for priming, followed by a protein-based vaccine boost134. This immunization
schedule results in the induction of a strong cellular immune response, as well as a
higher and more specific antibody response as compared to homologous
immunization135.
I hypothesize that DNA vaccines are an ideal vaccine platform for a nextgeneration anti-malaria vaccine, due to their ease of production and cost-effectiveness,
and their ability to induce robust cellular and humoral immunity, which is of key
importance for a pathogen with both extracellular and intracellular phases.
1.6: Summary
While the global incidence of malaria has decreased in the past decade, the
infection remains a significant global health concern. In 2019 there were approximately
229 million cases worldwide, of which 93% were in the WHO African Region136. Those
19

cases resulted in 409,000 fatalities, with a high burden in younger populations, as 67%
of cases occur in children under 5 years of age136. Nearly half of the world’s population is
at risk for malaria infection27. Malaria is caused by infection by Plasmodium parasites,
and while six species can cause disease in humans, Plasmodium falciparum (Pf)
remains the most prevalent malaria parasite, accounting for 99.7% of all cases in the
WHO African region136. Symptoms can arise 10-15 days after the infective mosquito bite,
and include fever, headache, and chills, which can progress to severe illness and
potentially death27.
The WHO Global Technical Strategy for Malaria 2016-2030 established a
number of goals to be achieved globally by 2030, including 1) reducing malaria case
incidence by 90% by 2030, 2) reducing malaria mortality by at least 90%, and 3)
eliminating malaria in at least 35 countries27. Malaria elimination is defined as the
interruption of local transmission of a specified malaria parasite species in a defined
geographical area as a result of deliberate actions27. Achieving these goals will require
varied approaches, including vector control approaches such as insecticide treated bed
nets and indoor spraying with residual pesticides. The inclusion of a vaccine into these
techniques has always been of paramount importance, and this importance continues to
grow as drug resistant strains of the parasite emerge27. The following chapters describe
the development of and immune mechanisms behind multiple synthetic DNA vaccines
targeting pre-erythrocytic stages of malaria infection. Understanding malaria infection,
the immune response elicited by vaccination, and the continued development of novel
vaccine strategies remain crucial elements in the world-wide battle against malaria.
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Figure 1.1: Plasmodium Life Cycle. Figure generated with BioRender©
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CHAPTER 2: The importance of liver localized T cells in
protection from malaria

Parts of this chapter were previously published in Vaccines:
Reeder, S. M., Reuschel, E. L., Bah, M. A., Yun, K., Tursi, N. J., Kim, K. Y., ... &
Perrin, B. (2020,January). Synthetic DNA Vaccines Adjuvanted with pIL-33 Drive
Liver-Localized T Cells and Provide Protection from Plasmodium Challenge in a
Mouse Model. Vaccines, 8(1), 21.

Introduction
As summarized above, infection in humans begins when the human is bitten by
an infected female Anopheles mosquito and inoculated with sporozoites, which then
travel through the blood or lymphatics, and invade hepatocytes. This chapter will focus
on the development of a pre-erythrocytic vaccine targeting liver stage antigens, and the
potential mechanisms of protection for the immunity it drives.
I hypothesize that LS proteins delivered by a synthetic optimized DNA plasmid
vaccine should induce protective immunity similar to that observed with live attenuated
parasite models (See Chapter 1.4). While there are a plethora of liver stage antigens, I
focused on the following antigens, which are expressed across Plasmodium spp.: EXP1,
profilin (PFN), EXP2, ICP, TMP21, and UIS3. EXP1 (exported protein 1) is a glutathione
transferase, located at the parasite-host interface, which efficiently degrades cytotoxic
hematin, and is associated with the metabolism of and susceptibility to artesunate, a
frontline anti-malarial drug137,138. EXP1 has been previously shown to be immunogenic in
a mouse model of malaria139. There is evidence in humans that EXP1 may be an
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important anti-malarial target, as a positive antibody response to EXP1 correlated with a
statistically significant decrease in malarial infection in children in Burkina Faso140.
Profilin (PFN) has been detected in all life cycle stages, including sporozoites and
merozoites, and abundant PFN expression suggests PFN is important for Plasmodium
life cycle progression141,142. Like all apicomplexans, Plasmodium utilizes a highly
specialized microfilament system for motility and host cell invasion, and profilin plays a
key role as an actin-sequestering protein143,144. It has been shown that disturbing
expression of PFN results in complete life cycle arrest145. Similarly to EXP1, exported
protein 2 (EXP2) is an integral vacuolar protein146. EXP2 resides primarily on the
vacuolar face of the PVM, and likely constitutes the membrane pore147. In Plasmodium,
inhibitor of cysteine proteases (ICP) has been shown to be necessary for malaria
transmission from mosquitos to mammals, sporozoite motility, erythrocyte invasion148,
and liver stage development149. While little is known about transmembrane protein 21
(TMP21), vaccination with TMP21 reduced liver stage parasite load in a mouse model
and has been shown to contribute to the protective immunity elicited by whole parasite
vaccinations150. The antigen UIS3 (upregulated in infective sporozoites-3) is a
membrane protein that is localized to the PVM in infected hepatocytes151 and interacts
directly with host liver-fatty acid binding protein (L-FABP)152. UIS3 is essential for early
liver stage development153 and vaccination with a ChAd63-MAV vaccine containing UIS3
has been shown to be partially protective in a mouse model154.
One of the strengths of the synthetic DNA vaccine platform is the ease with
which antigens can be co-formulated with each other and with molecular adjuvants in the
clinic155–158. Given the focus on induction of cellular immunity, we explored using
synthetic DNA-encoded plasmid IL-33 (pIL-33) as a molecular adjuvant. pIL-33 is a
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member of the IL-1 family, which although originally associated with Th2 immunity, has
been shown to facilitate the generation of protective Th1 and CD8 T cell immunity156.
pIL-33 has immunoadjuvant effects in an HPV-associated model for cancer
immunotherapy in which cell-mediated immunity is critical for protection and has been
shown to enhance potent antigen specific effector and memory T-cell immunity in a DNA
vaccine setting158. The ability to induce potent cell mediated immunity is important for a
vaccine against LS malaria, as is the fact that IL-33 is predominantly expressed at the
epithelial barrier as the first line of defense against pathogenic threats, activating a
variety of immune cells159, which may be relevant to the necessity for Plasmodium
sporozoites to transverse through the dermis before LS infection. Consequently, IL-33
was chosen as a molecular adjuvant for this study. Another strength of the DNA vaccine
platform is its ability to drive functional, localized cell mediated immunity (CMI). Prior
work studying the immunity from a hepatitis B DNA vaccine showed the ability of this
platform to drive vaccine specific CTLs to traffic to the liver, an organ that is known to be
tolerogenic and suppress T cell responses160. The ability of this platform to drive vaccine
specific CTLs in this location highlights the potential to drive relevant, functional CMI in
the context of a liver infection.
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Results
synDNA vaccine construct design and in vitro expression.
Previously identified LS proteins were optimized and encoded into a modified pVax
plasmid. Plasmid 1 contains an IgE leader sequence, the EXP1 gene sequence, a linker
sequence, and the PFN gene sequence. Plasmids 2, 3, 4, and 5 each contain an IgE
leader sequence, the gene sequence for EXP2, ICP, TMP21, or UIS3 respectively, and
an HA tag (Figure 2.1A). While all LS proteins selected are expressed across Plasmodium
spp., the synthetic optimized DNA vaccine constructs were matched for Plasmodium yoelii
(Py), to reflect the planned challenge model.
In vitro expression of Py constructs in transfected 293T lysates was detected by
western blot. Expression was confirmed for plasmids 2-5 by detection of the HA tag.
Expression for plasmid 1, which lacked an HA tag, was confirmed by probing with postimmune sera from mice immunized with the construct. GFP transfection was used as a
negative control (Figure 2.1B).

Py LS vaccine constructs delivered individually elicit a robust and
polyfunctional T cell response
To assess the cellular immune response to LS antigen vaccination, groups of 5 mice
were immunized 4 times at 3-week intervals with one of the five constructs individually, or
the empty vector pVax as a negative control. One week after final immunization
splenocytes were collected for immune analysis and antigen specific cytokine production
was assessed by IFNγ ELISPOT and flow cytometry. All 5 constructs induced detectable
IFNγ cellular responses with EXP1_PFN and ICP being the highest inducers. EXP2 and
UIS3 induced lower, but still robust levels of IFNγ secreting cells, and TMP21 induced
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readily detectable, but the lowest, levels of IFNγ secreting cells (Figure 2.2A). The
functional profile of antigen specific CD4+ (Figure 2.2B) and CD8+ (Figure 2C) T cells was
analyzed by flow cytometry. Mono-, double-, and triple-positive CD4+ and CD8+ T cells
releasing the cytokines IFNγ, TNFα, and IL-2 are shown. CD4+ T cells responded most
highly to EXP1, EXP2, ICP, and UIS3. In contrast, CD8+ T cells responded most highly to
PFN and EXP2. As expected, ELISPOT and flow cytometry responses in mice immunized
with the empty vector control, pVax, were negligible (Figure 2.2).

Co-formulated Py LS vaccines delivered with and without plasmid IL-33
adjuvant elicit a robust and polyfunctional T cell response
To investigate the immunogenicity of co-formulated vaccine constructs groups of 5
mice were immunized 4 times at 3-week intervals with combinations of constructs
(EXP1_PFN alone, EXP2 and ICP, TMP21 and UIS3, and all constructs together) with
and without the molecular adjuvant pIL-33 all delivered in a single injection site.
Splenocytes were collected for analysis of the cellular immune response using IFNγ
ELISPOT and flow cytometry. All immunization groups saw an upwards trend in IFNγ
ELISPOT responses with the addition of pIL-33 (Figure 2.3A). The functional profile of
CD4+ (Figure 2.3B, D, E, and F) and CD8+ (Figure 2.3C, G, H, and I) T cells was analyzed
by flow cytometry. In the mice immunized with EXP1_PFN alone, CD4+ T cells respond
more highly to EXP1 and this phenotype is enhanced in the adjuvanted group (Figure
2.3D). By contrast, as seen in Figure 2.3G, CD8+ T cells respond more highly to PFN, and
this phenotype is also enhanced in the adjuvanted group. In mice immunized with EXP2
+ ICP, CD4+ T cells responded quite similarly to EXP2 and ICP; however, in the
adjuvanted group the EXP2 response was preferentially increased (Figure 2.3E). CD8+ T
cells responded more highly to EXP2; however, this phenotype was not recapitulated in
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the adjuvant group (Figure 2.3H). In the mice immunized with TMP21 + UIS3, CD4+ T
cells responded more highly to UIS3 (Figure 2.3F), a phenotype that did not change with
the addition of pIL-33, whereas CD8+ T cells responded more highly to TMP21 (Figure
2.3I). As expected, ELISPOT and flow cytometry responses in mice immunized with the
empty vector control, pVax, or pIL-33 alone were negligible (Figure 2.3A, B, and C).

Py LS antigen vaccination elicits a robust and polyfunctional antigen specific T
cell response in the liver which is enhanced with the addition of plasmid IL-33
The functionality of liver localized antigen specific T cells was investigated using the
EXP1_PFN construct, as EXP1_PFN consistently produced the most robust T cell
response. Mice were immunized 3 times at 3-week intervals with the EXP1_PFN construct
with and without pIL-33. One week after the final immunization lymphocytes were isolated
from both liver and spleen of immunized mice and their phenotype and functional capacity
was measured using flow cytometry and ELISPOT assays. The percentage of CD8+ cells
in the liver expressing CXCR6, a chemokine receptor important for trafficking to the liver87,
was significantly increased from 40% without co-delivery of pIL-33 to 60% with the addition
of pIL-33 (Figure 2.4A) while the expression of CXCR6 on CD8+ cells in the spleen was
10-fold lower (Figure 2.4B) than that on CD8+ cells in the liver. This suggests an
improvement of trafficking to the liver with the addition of pIL-33. As seen previously, the
addition of pIL-33 increased antigen specific IFNγ ELISPOT responses in the spleen
(Figure 2.4D) and interestingly, also in the liver (Figure 2.4C). Further investigation of the
functionality of the liver localized T cells using flow cytometry revealed that pIL-33 not only
increased the percentage of IFNγ+TNFα+IL-2+ (triple positive), IFNγ+, and IL-2+ CD4+
cells (Figure 4G) and IFNγ+ CD8+ (Figure 2.4H) cells from the spleen, but also increased
the percentage of IFNγ+ CD4+ (Figure 2.4E) and CD8+ (Figure 2.4F) cells from the liver.
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Vaccine delivered with and without adjuvant elicits antigen-specific antibody
responses
Vaccine induced antibody production was assayed by immunofluorescence. Hepa16 cells, were transfected with each DNA vaccine construct. Two days post transfection the
cells were probed with post-immune sera from mice immunized with the respective DNA
construct (with or without pIL-33) and probed with a fluorescently tagged secondary
antibody. Mice immunized with EXP1_PFN showed the most positive staining indicating
the highest antibody response. EXP2, ICP, and UIS3 showed intermediate antibody levels
and TMP21 showed the lowest levels of antibody induction (Figure 2.5). The addition of
pIL -33 did not appear to alter the amount of detectable antibody binding (Figure 2.5).
However, we cannot conclude whether or not this antibody response is important for the
observed immunity, as it is unknown whether these Plasmodium proteins would be
available for antibody binding in a physiologically relevant context. It is important to note
that while this assay shows the presence of antibodies elicited by vaccination, it does not
provide quantitative information on antibody level or titer.

Plasmodium LS synDNA vaccine is protective against malaria infection in a
mouse model
To assess the ability of these DNA vaccine constructs expressing LS malaria antigens
to protect against malaria, groups of 7-8 mice were immunized 4 times at 3-week intervals
with combinations of constructs (EXP1_PFN alone, EXP2 and ICP, TMP21 and UIS3, and
all constructs together) with and without the molecular adjuvant pIL-33, and then
challenged 9 weeks later with intravenous delivery of 250 infectious P. yoelii sporozoites.
Blood was collected daily following sporozoite injection for blood smears to check for the
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presence of blood stage parasites, i.e. patency (Figure 2.6A). All empty vector and pIL-33
alone immunized animals had visible blood stage parasites 4 days after challenge. 7188% of animals immunized with DNA vaccine delivered without adjuvant were completely
protected from patency, with parasitemia in the few animals who were not protected being
delayed 1.5-2 full days. 100% of animals immunized with any combination of constructs
in addition to pIL-33 were completely protected from blood stage parasitemia indicating
sterile protection in these groups (Figure 2.6B). Examples of the blood smears from each
group showing the presence of blood stage parasites only in the pVax and pIL-33 alone
groups are shown in Figure 2.6C.
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Discussion
Synthetic DNA delivered by adaptive electroporation (EP) is a particularly
attractive vaccine platform for a LS antigen malaria vaccine because of its ability to
induce robust CD8+ T cell responses. In clinical studies, synDNA vaccines delivered
with EP have proven highly effective in small and large animal models of infectious
disease and cancer, and have demonstrated the ability to drive a tissue infiltrating
population of antigen specific CD8 T cells157. In recent years, DNA vaccines for HPV157,
HIV161,162, Zika155, and Ebola163 among others have moved into human clinical trials.
Here, I present a novel approach using synthetic DNA vaccination with LS antigens in
conjunction with a plasmid encoded molecular adjuvant IL-33 which together drive
antigen specific liver associated CD8 T cells and achieve complete protection from blood
stage disease in a virulent Plasmodium sporozoite challenge in the mouse model.
This study demonstrates that a synDNA vaccine targeting liver stage
Plasmodium antigens drives an antigen specific liver localized T cell population. Further,
this study illustrates the potential efficacy of a synDNA vaccine platform targeting liver
stage proteins in providing protection from malaria infection in this model. I show that a
synDNA vaccine targeting EXP1, PFN, EXP2, ICP, UIS3, and TMP21, in combination or
alone, elicits a robust T cell response, as well as the production of antibodies against
liver stage malaria. The use of the molecular adjuvant pIL-33 increases the immune
response to vaccine and results in 100% protection from blood stage disease after
sporozoite challenge, where non adjuvanted vaccine results in 70-88% protection from
blood stage disease. A potential contributor to this increased protection in the
adjuvanted groups is the increase in antigen responsive liver associated T cells, as well
as their polyfunctionality as demonstrated by enhanced cytokine poly-positivity in
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adjuvanted groups. Additional focus on LS antigens as a component of a malaria
vaccine is warranted, potentially in combination with sporozoite antigens such as CSP.
RTS,S and R21 combinations might be particularly interesting164–166. Altogether, the data
suggest cell-mediated immunity as well as antibodies should be considered when
designing anti-malarial vaccines and support the continued examination of liver stage
antigens as components of a prophylactic vaccine.
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Materials and Methods
Construct design
Protein sequences for selected Plasmodium antigens were accessed on
PlasmoDB, the Plasmodium genomics resource (EXP1: PY04421, PFN: PY03207,
EXP2: PY05892, ICP: PY17X_0816300, TMP21: PY06414, UIS3: PY03011). While all
antigens selected are expressed across Plasmodium spp., the vaccine constructs were
matched to Plasmodium yoelii 17X (Py), to reflect the planned challenge model, which
was P.yoelii 17X-NL (non-lethal) strain. The synthetic DNA vaccine constructs were
codon optimized for mice and humans and were incorporated into a modified pVax
vector with an IgE leader sequence, and an HA tag where indicated in Figure 2.1.
Western blot
In order to assess in-vitro expression of the vaccine constructs, 293T cells
(ATCC® CRL-3216™) were plated in 6-well plates at 0.5-0.7x106 cells per well in 2 mL
DMEM (Gibco) + 10% FBS and incubated overnight at 37 °C in 5% CO2. Cells were
transfected with 5 μg DNA using TurboFectin 8.0 transfection kit and incubated for 48 hr.
48 hours after transfection, supernatants and lysates were collected for western blot
analysis. Samples were prepared with NuPAGE LDS Sample Buffer, 10X Reducing
Agent, and deionized water. Sample mixture was incubated at 70 °C for 10 minutes. 25
μl of sample was loaded per well onto an Invitrogen NuPAGE Bis-Tris Gel in 1X NuPage
MOPS running buffer. The gel was run for 150 V for 50 min. Protein was transferred to a
methanol activated PVDF membrane using the iBlot 2 Dry Blotting System (Life
Technologies). The membrane was blocked for 1 hr at room temperature with Li-Cor
Odyssey Blocking Buffer followed by overnight incubation at 4 °C with primary antibody.
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Primary antibody was either an anti-HA antibody (ThermoFisher) to detect expression of
the constructs which contain an HA tag, or post-immune sera collected from mice
immunized with the construct to detect expression of the EXP1_PFN construct which did
not have an HA tag. After washing, the membrane was incubated for 1 hr at room
temperature with IRDye labeled secondary antibody (Li-Cor) and then imaged using an
Odyssey CLx imager.
Immunization and CELLECTRA electroporation
Female BALB/C mice were ordered from the Jackson Laboratory aged 6-8
weeks and were housed in the Wistar Institute Animal Facility. Mice were immunized
with 25 μg DNA vaccine construct with or without 30 μg of plasmid pIL-33 delivered
intramuscularly using the CELLECTRA 3P adaptive constant current electroporator167.
When mice were immunized with a cocktail of antigens, 25 μg of each DNA vaccine
construct was used. Depending on the experiment, mice were immunized 4 or 3 times at
3-week intervals. Blood was collected 1 week post each vaccination for sera isolation.
One week post final immunization mice were euthanized and splenocytes and
hepatocytes were collected for immune analysis.
Immune Cell Isolation
After euthanasia, liver and spleen tissue were removed for immune cell isolation.
Before liver excision, the hepatic portal vein exiting the liver was cut and 5-10 ml of cold
PBS solution was administered through the left ventricle to profuse the liver until
blanched. Once perfused the liver was removed and placed in cold complete media
(DMEM + 10% FBS + 20 mM HEPES + 1X Pen/Strep). Livers were quickly
homogenized for 1 min at normal speed using a Stomacher 80 (Seward). Homogenates
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were transferred to 6-well plates with 10 ml of digest media (DMEM + 20 mM HEPES +
0.1 mg/ml Collagenase 4 + 0.02 mg/ml DNase) added and plates were incubated at 37
°C for 30 min. Cells were filtered through a 100 μm mesh strainer, rinsed with PBS, and
then centrifuged at 300 rpm for 1 min. The supernatant containing hepatocytes was
transferred to a new tube and spun down for 5 min at 1500 rpm. The cell pellet was
resuspended in 40% Percoll (Sigma-Aldrich), underlaid with 80% Percoll, and spun at
3000 rpm for 20 min with slow acceleration and deceleration. Hepatocytes at the
interface of the two Percoll layers were removed and diluted in complete media, then
counted using a COUNTESS II (Invitrogen) and trypan blue (Gibco).
Spleens were removed and placed in RPMI + 10% FBS + 1X Pen/Strep (R10).
Spleens were homogenized for 1 min on high using a Stomacher 80. The cell solution
was filtered through a 100 μm strainer and spun down for 10 mins at 1200 rpm. Cells
were resuspended in 5 ml ACK lysis buffer (Gibco) and incubated for no more than 5
min. After washing with PBS, cells were spun for 10 min at 1200 rpm. Splenocytes were
then resuspended in 20 ml of R10 and counted.
ELISPOT
Mouse IFN-γ ELISpot PLUS (Mabtech) plates were used as directed. Briefly,
plates were washed with PBS and blocked with R10 for 30 min. Wells were seeded in
triplicate with 200,000 cells in 100 μl R10. Cells were stimulated with peptide pools of
15mers overlapping by 11 amino acids spanning the entire vaccine antigen at a final
concentration of 5 μg/ml per peptide. R10 and Concanavalin A were used as negative
and positive controls, respectively. Plates were incubated for 18 hr at 37°C with 5% CO2.
Plates were developed as directed, scanned, and counted using a CTL ImmunoSpot S6
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Universal Analyzer. Data was exported to Microsoft Excel and GraphPad Prism 8 for
analysis.
Flow cytometry
Wells were seeded with 1,000,000 cells in 100 μl of R10. Cells were stimulated
with peptides at a final concentration of 5 μg/ml per peptide in the presence of Protein
Transport Inhibitor (eBioscience). R10 and Cell Stimulation Cocktail (eBioscience) were
used as negative and positive controls, respectively. Plates were incubated for 6 hr at 37
°C with 5% CO2. Following incubation, cells were washed with PBS, and stained with
Live/Dead fixable aqua dead cell stain kit (ThermoFisher) in PBS. Cells were then
stained for extracellular markers in 1% FBS in PBS (FACS buffer), fixed and
permeabilized with BD Fix/Perm, stained for intracellular markers and cytokines in BD
perm/wash, resuspended in FACS buffer, and run on BD LSRII flow cytometer (BD
Biosciences). Splenocytes and hepatocytes were stained with following panel: LiveDead
Aqua (Invitrogen, L34957), CD19-V450 (BDHorizon, 560375), CD3-AF700 (BioLegend,
100216), CD4-FITC (BD Pharmingen, 553047), CD8-BV605 (BioLegend, 100744), IFNγAPC (BioLegend, 505810), TNFα-PE (eBioscience, 12-7321-82), IL-2-PE-Cy7
(eBioscience, 25-7021-82) and CXCR6-BV421 (Biolegenend, 151109). Gates were set
using FMOs for each stain. Data were exported and analyzed in GraphPad Prism 8.1.1.
Immunofluorescence
Hepa1-6 cells (a cell line derived from mouse liver cells, ATCC® CRL-1830™)
were plated on pre-coated Poly-D-Lysine (Corning) 8 chambered wells at 100,000 cells
per well in 400 μl DMEM (Gibco) + 10% FBS and incubated overnight at 37 °C in 5%
CO2. Cells were transfected with 1 μg DNA using Thermofisher Lipofectamine 3000
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transfection kit and incubated for 48 hr. Media was removed, and cells were washed
twice with PBS (Gibco) for 5 min and then fixed with 2% PFA in PBS for 5 min. Cells
were again washed twice with PBS followed by blocking in 5% goat serum + 0.05%
Tween-20 for 1 hr at room temperature followed by two 5 min PBS washes. Cells were
incubated with 500 μl pooled mouse sera at a 1:50 dilution in 1% BSA + 0.05% Tween20 in PBS buffer at room temp for 1 hr. After washing three times with PBST (0.05%
Tween-20 in PBS) for 5 min each, cells were incubated with 300 μl of secondary
antibody diluted in 1% BSA + 0.05% Tween-20 in PBS buffer at room temp for 1 hr.
Cells were washed with PBST for 5 min, then incubated with DAPI (Hoechst 33342
Fluorescent Stain, Thermo Scientific) at a 1:5,000 dilution in PBST for 5 min, followed by
a final wash with PBST to remove unbound DAPI stain. Cells were imaged using a Leica
TCS SP5 confocal microscope.
Mosquito feeding and sporozoite extraction
Six-to-eight-week-old female Swiss Webster (SW) mice (purchased from Envigo,
Indianapolis, IN) were used for mosquito feeding experiments to generate salivary gland
sporozoites for challenge studies. All animal handling was conducted according to the
approved protocols of the Institutional Animal Care and Use Committee (IACUC) of
Tulane University (Protocol # 4258R). Mosquito feeding experiments were conducted
with P. yoelii 17X-NL wild-type parasites as previously described168–170. Briefly, SW mice,
treated with phenylhydrazine, are injected intravenously with 1 million blood stage
parasites, and on day 3 post infection an exflagellation assay is used to confirm the
availability and formation of P. yoelii male microgametes. Mosquito feeding is conducted
by allowing about 150 female mosquitoes or less to feed on a mouse anesthetized with
ketamine/xylazine for 15 min. Salivary gland sporozoite extraction was conducted by
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dissection of the salivary glands of infected female mosquitoes at day 14 or 15 post
mosquito feeding (pmf) in RPMI incomplete medium, as previously described 81,171,172.
Collected salivary glands were mechanically disrupted with a pestle and the salivary
gland sporozoites were counted using a hemocytometer. Doses of 250 sporozoites in
150 µl incomplete RPMI were prepared as previously described86,87,137.
Challenge study
Six-to-eight-week-old female BALB/cJ mice (purchased from Jackson
Laboratories, Bar Harbor, ME) were used for challenge experiments. Mice were put
under a red heating lamp 5-10 min before injection. Each dose of 250 sporozoites was
loaded in 27G insulin syringes and was injected intravenously in the tail vein of
immunized mice. Giemsa-stained thin blood smears were checked every day (at least 50
whole microscopy fields at 1000x) for blood stage parasites, starting from day 3 until day
10 post infection81,171,172.
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Figures

Figure 2.1 DNA vaccine construct design and in vitro expression. (A) Schematic
diagram of Plasmodium yoelii (Py) gene inserts used to generate the codon-optimized
DNA vaccine constructs. The schematic details leader sequence (IgE), gene insert, and
presence or absence of HA tag. All constructs with the exception of EXP1_PFN contain
an HA tag. (B) Expression of Py proteins detected by SDS-polyacrylamide gel
electrophoresis and western blot of lysate from transfected 293T cells. Protein
expression was detected by probing for the HA tag when present with an anti-HA
antibody, or with immune sera from immunized mice for the EXP1_PFN plasmid.
GFP is included as a negative control.
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Figure 2.2 Functional profile of cellular immune responses elicited by
individual Py DNA vaccines in mice. Mice were immunized 4 times at 3-week
intervals with the indicated co-formulation of vaccine constructs with and
without plasmid IL-33. Splenocytes were collected 1 week after the final
immunization. (A) The Py antigen-specific cellular immune response measured
by IFNγ ELISPOT of splenocytes 1 week after final immunization with the
indicated Py DNA vaccine. Cells were stimulated for 18 hr with peptide pools
encompassing the entire protein. A one-way ANOVA with Dunnet’s multiple
comparison test was used to compare each vaccine group to the pVax control
group. (B,C) The Py antigen-specific cytokine production profile of CD4+ (B)
and CD8+ (C) T cells from spleens 1 week after the final immunization with the
indicated Py DNA vaccine. Cells were stimulated with pooled peptides for 6
hr, stained for intracellular production of IFNγ, TNFα, and IL-2, and then
analyzed by flow cytometry. The bar graph shows subpopulations of mono-,
double-, and triple-positive CD4+ and CD8+ T cells. A 2-way ANOVA with
Tukey’s multiple comparisons test was used to compare cytokine production
between each vaccine group and the pVax control group. Asterix color
indicates which cytokines were significantly different between vaccine and
control. * = p < 0.05, ** p < 0.01, *** = p < 0.001, **** = p < 0.0001. Values
represent mean responses in each group (n = 5) ± SEM.
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Figure 2.3 Functional profile of cellular immune responses elicited by co-formulated Py
DNA vaccines in mice. Mice were immunized 4 times at 3-week intervals with the
indicated co-formulation of vaccine constructs with and without plasmid IL-33.
Splenocytes were collected 1 week after the final immunization. Immunization groups
were: All vaccine constructs with or without IL-33, EXP1_PFN (exported protein
1_profilin) with or without IL-33, EXP2 (exported protein 2) and ICP (inhibitor of cysteine
proteases) with or without IL-33, and TMP21 (transmembrane protein 21) and UIS3
(upregulated in infective sporozoites-3) with or without IL-33. (A) The Py antigen-specific
cellular immune response induced by the indicated Py DNA vaccine co-formulation
measured by IFNγ ELISPOT. Cells were stimulated for 18 h with peptide pools
encompassing the entire protein. T-tests were used to compare groups with and without
IL-33. (B–I) The Py antigen-specific cytokine production profile of CD4+ (D–F) and CD8+
(G–I) T cells induced by the indicated Py DNA vaccine co-formulation. Cells were
stimulated with pooled peptides for 6 h, stained for intracellular production of IFNγ,
TNFα, and IL-2, and then analyzed by flow cytometry. The bar graph shows
subpopulations of mono-, double-, and triple-positive CD4+ and CD8+ T cells. Two-way
ANOVAs with Tukey’s multiple comparison test were used to compare vaccine groups
against the same group adjuvanted with IL-33. Asterix color represents the corresponding
cytokine groups. * = p < 0.05, ** p < 0.01, *** = p < 0.001, and **** = p < 0.0001. Values
represent the mean responses in each group (n = 5) ± SEM.
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Figure 2.4 Synthetic DNA vaccines drive antigen-specific liver resident T cells. Mice
were immunized 3 times at 3-week intervals with the EXP1_PFN vaccine construct with
and without plasmid IL-33. Lymphocytes were isolated from liver and spleen 1 week
after the final immunization. (A, B) The proportion of liver resident/homing CD8+ T
cells. Lymphocytes from liver (A) or spleen (B) were stained for extracellular CXCR6
and analyzed by flow cytometry. Paired t-tests were used to compare % CXCR6
positivity on CD3+CD8+ T cells across vaccine groups and against the pVax control. (CD) The Py antigen-specific cellular immune response in liver (C) and spleen (D)
measured by IFNγ ELISPOT. Cells were stimulated for 18 hr with peptide pools
encompassing the entire protein. T-tests were performed to compare IFNγ production
across vaccination groups and against the pVax control. The Py antigen-specific
cytokine production profile of CD4+ (E,G) and CD8+ (F,H) T cells from the liver (E-F)
and spleen (G-H). Cells were stimulated with pooled peptides for 6 hr, stained for
intracellular production of IFNγ, TNFα, and IL-2, and then analyzed by flow cytometry.
The bar graph shows subpopulations of mono-, double-, and triple-positive CD4+ and
CD8+ T cells. 2-way ANOVAs with Tukey’s multiple comparison test were used to
compare cytokine production across vaccination groups and against the pVax control.
The pie chart shows the proportion of each cytokine subpopulation. Values represent
mean responses in each group (n = 5) ± SEM.
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Figure 2.5 Antibodies elicited by Py
DNA vaccines in mice. Hepa1-6 cells were
transfected with the DNA vaccine construct
listed on the left. Cells were then probed
with pooled mouse post-immune sera
collected 1 week after the last
immunization. An anti-mouse-IgG-AF488
was used as a secondary antibody to detect
the presence of anti-Py antigen antibodies.
DAPI staining shows cell nuclei. White text
in the top left corner of each field indicates
post-immune sera vaccine group.
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Figure 2.6 DNA vaccine expressing Py LS antigens provides protection from blood stage
disease after sporozoite challenge. (A) Vaccine and challenge timeline. Balb/c mice were
immunized 4 times at 3-week intervals with the indicated vaccine co-formulations.
Immunization groups were: All vaccine constructs with or without IL-33, EXP1_PFN with or
without IL-33, EXP2 and ICP with or without IL-33, and TMP21 and UIS3 with or without IL33. Mice were then challenged by injection of 250 P. yoelii sporozoites. Blood smears were
examined daily for signs of blood stage disease. (B) Survival curves showing protection from
evidence of blood stage parasites. Log-rank tests were used to compare groups and p-values
less than the Bonferroni-corrected threshold are indicated. * = p < 0.05, ** p < 0.01, *** = p <
0.001, **** = p < 0.0001. (C) Example blood smears from each group. Red arrows indicate
blood stage parasites.
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CHAPTER 3: The importance of anti-CSP antibodies in
protection from Malaria

Introduction
Chapter 2 addressed our efforts developing a pre-erythrocytic vaccine targeting
liver stage antigens, which had the goal of eliciting cell mediated immunity targeting
infected hepatocytes. This chapter will focus on our efforts developing a pre-erythrocytic
vaccine to intercede before the parasite even establishes infection in hepatocytes; the
studies outlined in this chapter aimed to develop an anti-sporozoite antibody response to
prevent sporozoite invasion of hepatocytes, and thus prevent progression to
symptomatic disease.
As discussed in chapter 1.4, RTS,S/AS01 (RTS,S) is one of the longest studied
candidate vaccines, and is focused on generating immunity to CSP, the
circumsporozoite protein of Plasmodium falciparum (Pf). RTS,S is a recombinant
protein-based vaccine comprised of a fragment of CSP containing a section of the
repeat region, and the T cell epitopes of the c-terminus attached to the Hepatitis B
surface antigen protein, and delivered with additional HbsAg to encourage the formation
of virus-like-particles in yeast, which are then harvested and administered with an
adjuvant to humans to generate a T cell and antibody response. This is the only vaccine
to show significant reduction in malaria in young children living in endemic regions. A
phase 3 trial which spanned 5 years demonstrated that children aged 5-17 months who
received 4 doses of RTS,S had a 39% reduction in malaria cases, and a 29% reduction
in severe malaria cases over 4 years of follow-up67. After positive recommendations by
WHO advisory boards, three countries, Ghana, Kenya, and Malawi began introducing
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RTS,S in 201927. In the coming years, the Malaria Vaccine Implementation Programme
(MVIP) will assess the feasibility of administering the recommended 4 doses of the
vaccine in children, the potential role in reducing childhood death, and the safety of
RTS,S in the context of routine use68 as well as in specific important subpopulations.
An important advance in malaria vaccines is the development of a novel
polyvalent immunogen R21, a recent anti-malaria vaccine candidate, which builds on the
knowledge gained from RTS,S. In contrast to RTS,S, R21 delivers a higher ratio of CSP
to the Hepatitis B surface antigen (HBVsAg), which is in a 1 to 1 ratio as opposed to the
1 to 4 ratio of RTS,S5. Thus far R21 has proven to be well tolerated and immunogenic in
early trials, as well as protective in a controlled human malaria infection study
(CHMI)69,70. The correlates of immunity which have emerged from these malaria
vaccines support the importance of anti-CSP antibodies primarily but also suggest a role
for T cells for imparting protection from Plasmodium infection67,69–74.
The circumsporozoite protein (CSP) has long been a vaccine candidate of
interest. CSP is the major component of surface proteins on sporozoites, forming a
dense coat on the parasite during this stage of the life cycle173,174. CSP is composed of
three regions, (1) an N-terminus that binds heparin sulfate proteoglycans, (2) a four
amino acid repeat region, and (3) a C-terminus that contains a thrombospondin-like type
I repeat (TSR) domain. Native CSP on the surface of sporozoites appears as a
glycosylphosphatidylinositol-anchored, flexible rod-like protein175,176. The central repeat
region contains the immunodominant B cell epitope177,178. The C-term contains the TSR,
T cell epitopes, as well as B cell epitopes179,180. The N-terminus region is also of
importance, as it has been shown to be involved in liver attachment181, and interacts with
liver cells through heparin sulfate; antibodies against this region have been shown to be
inhibitory in a sporozoite invasion assay182. As for overall structure, it has been shown
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that CSP forms a long, flexible, rod-like superhelix composed of regular β-turns175,176.
However, this structure undergoes conformational changes during the parasite’s life
cycle36. As referenced above, CSP interacts with heparan sulfate proteoglycans on the
surface of hepatocytes during the invasion process35,183,184. This interaction is contingent
on processing of the N-terminus and the subsequent conformation change36. Further, a
synthetic peptide corresponding to L86 to G100 blocks salivary gland invasion, showing
the biological importance of the n-terminal domain185. The processing of CSP by a
parasite cysteine protease, and subsequent cleavage, is specifically associated with the
decision between productive invasion and cell transversal35,174, as the proteolytic
cleavage of CSP regulates the switch to an open adhesive confirmation, whereas the
masking of this domain maintains the sporozoite in a migratory state173.
This knowledge of the importance of all three domains of CSP, as well as the
importance of its confirmation, shaped our decisions for construct design. To that end,
five synDNA constructs were designed with variations hypothesized to provide relevant
expression and folding, or for testing the importance specific domains of CSP for
inducing protection (Figure 3.1). The construct “3D7” contains the unadulterated full
length native CSP sequence from the Pf 3D7 strain. The construct “GPI1” contains the
CSP sequence from the Pf 3D7 strain, with a mammalian GPI anchor substituted in for
the native protozoan GPI anchor. The construct “ΔGPI” contains the native CSP
sequence from the Pf 3D7 strain without a GPI anchor. The construct “TM” contains the
CSP sequence from the Pf 3D7 strain with a mammalian transmembrane domain
substituted in for the native protozoan GPI anchor. The construct “DD2_3D7” contains
the N-terminus region of CSP from the Pf DD2 strain, linked to the n-terminus region of
CSP from the Pf 3D7 strain. These five variations on CSP tested soluble vs secreted
forms, different cell membrane attachment approaches, oligomerization, and the
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importance of the domains of CSP in immunization and challenge studies. Mice
immunized with 3D7, dGPI, GPI1, or TM all developed robust antibody responses
against both recombinant CSP (rCSP) as well as the NANP7 peptide, whereas mice
immunized with DD2 had a negligible antibody response. Additionally, all 5 constructs
induced IFNγ cellular responses with ΔGPI being the highest inducer. Finally, mice
immunized with ΔGPI had the highest inhibition of liver stage infection in a murine
challenge model. The vaccine with the highest immunogenicity and most robust
protective efficacy was ΔGPI.
Additionally, based on previous work in the lab demonstrating the ability of DNA
launched nanoparticles to assemble in vivo186, I developed mimics of the leading CSP
vaccines, RTS,S and R21 (both recombinant protein based polyvalent vaccines), and
tested them side by side with our other DNA vaccines. SynDNA RTS,S (dRTS,S) and
synDNA R21 (dR21) displayed similar immunogenicity and protective efficacy to their
protein counterparts. Both dRTS,S and dR21 elicited anti-CSP antibodies, and only
dRTS,S elicited anti-HBsAg antibodies, where dR21 did not, recapitulating what has
been seen in prior studies69. Additionally, both dRTS,S and dR21 vaccinated mice
produced IFNy in response to stimulation with CSP antigen. Consequently, dRTS,S and
dR21, as well as ΔGPI, demonstrated high protective efficacy against a rigorous
infectious mosquito bite murine malaria challenge.
Thus we observe that a uniquely designed synthetic DNA vaccine, ΔGPI, as well
as genetically encoded RTS,S and R21 form polyvalent protein structures which elicit a
robust anti-CSP antibody response, as well as a T cell response which was associated
with protection from Plasmodium infection. Additional study of this approach appears
warranted based on our demonstration of robust immunogenicity in the putative
correlates of protection for malaria infection, specifically the high titer antibody response,
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the high antigen specific IFNy production, and the sterilizing immunity demonstrated in
challenge.
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Results
synDNA CSP vaccine construct design and in vitro expression
Five synDNA constructs were designed with variations hypothesized to increase
immunogenicity. All constructs target Plasmodium falciparum (Pf). Each construct was
synthesized and then inserted into a pVax backbone, with an added IgE leader
sequence as described128. The construct “3D7” contains the unadulterated full length
native CSP sequence from the Pf 3D7 strain. The construct “GPI1” contains the CSP
sequence from the Pf 3D7 strain, with a mammalian GPI anchor substituted in for the
native protozoan GPI anchor. The construct “ΔGPI” contains the native CSP sequence
from the Pf 3D7 strain without a GPI anchor. The construct “TM” contains the CSP
sequence from the Pf 3D7 strain with a mammalian transmembrane domain substituted
in for the native protozoan GPI anchor. The construct “DD2_3D7” contains the Nterminus region of CSP from the Pf DD2 strain, linked to the n-terminus region of CSP
from the Pf 3D7 strain. These five variations on CSP tested soluble vs secreted forms,
different cell membrane attachment approaches, and the importance of domains of CSP
in immunization and challenge studies. In vitro expression of each construct was verified
by western blot. Because the detection Ab used was directed against the repeat region,
the construct DD2 would not be readily detected by this method (Figure 3.1B). The
synDNA vaccine construct ΔGPI exhibited the highest expression in the supernatants
collected from transfected cells (Figure 3.1C). This may indicate a superior ability to be
secreted from transfected myocytes in vivo, and thus superior immune activation, though
further study is needed.
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synDNA CSP vaccine constructs elicit a robust immune response
To assess the immunogenicity of each unique construct, groups of five BALB/c
mice were immunized with 25 µg of vaccine four times, three weeks apart (week 0, 3, 6,
and 9) (Figure 3.2A). pVax was included as an empty vector (negative) control. Sera
was collected to assess the antibody response. Previous work has shown that
antibodies are of critical importance for targeting CSP, particularly the NANP region187.
The sera from immunized mice was used as a primary antibody to probe ELISA plates
which had been coated with either recombinant CSP, or the NANP peptide alone. The
monoclonal antibody 2A10188 was used as a control. Mice immunized with 3D7, ΔGPI,
GPI1, or TM all developed robust antibody responses against both rCSP and the NANP
peptide. Mice immunized with DD2 induced a negligible antibody response, and those
immunized with the empty vector control had no antibody response (Figure 3.2B-C). In a
parallel experiment, splenocytes were collected one week after final immunization for
immune analysis and antigen specific cytokine production was assessed by IFNγ
ELISPOT. All 5 constructs induced IFNγ cellular responses with ΔGPI being the most
potent. 3D7, GPI1, and TM induced lower, but still robust levels of IFNγ secreting cells,
and DD2 induced readily detectable, but the lowest, levels of IFNγ secreting cells (Figure
3.2D). The bulk of the IFNγ response is directed against the n-terminus of CSP, follow in
reactivity by the c-terminus. The NANP repeat region induced a low level of IFNγ. 3D7,
the only construct designed to contain a Pf GPI anchor, did elicit a response to the GPI
anchor (Figure 3.2D).
synDNA CSP vaccine constructs are protective against IV sporozoite Pf challenge
Groups of five BALB/c mice were immunized with 25 µg of vaccine four times,
three weeks apart (weeks 0,3,6,9) as in Figure 3.2A. Two weeks after the last boost,
mice were inoculated with 250 sporozoites IV. Immunized and non-immunized BALB/c
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mice were challenged with P.berghei sporozoites expressing both the P.falciparum
circumsporozoite protein (CSP) and luciferase. 42 hours after intravenous injection of
250 sporozoites, mice were intraperitoneally injected with 100 μl of D-luciferin (30
mg/mL), anesthetized and liver luminescence was measured with the Perkin Elmer IVIS
Spectrum Imaging System to assay liver loads. Inhibition of liver infection is expressed
as a function of relative infection compared to naive mice. Mice immunized with ΔGPI
have the highest inhibition of liver infection (64.17%) out of the immunized groups, while
the positive control, which was 100 µg of the MAb 311187 delivered 16 hours before
challenge showed an 80% inhibition of liver stage infection (Figure 3.2E-G). ΔGPI
showed significant vaccine induced protective immunity in this challenge model (Figure
3.2E-G).
DNA encoded CSP polyvalent vaccines
We were encouraged by these initial challenge results, and wanted to compare
them to the important standards in the field (RTS,S and R21) which are more complex
vaccine formulations, both of which form polyvalent particles. However, research
acquisition of the protein forms was limited. Thus to compare such more polyvalent
forms, we moved to develop genetically encoded DNA vaccines in the form of dR21 and
dRTS,S. The sequences for R21189 and RTS,S190 were retrieved, and then modified to
include changes in RNA and codon bias, as well as the addition of an efficient IgE leader
sequence, to generated dR21 and dRTS,S. The final constructs were inserted into a
pVax backbone (Figure 3.3A). The dR21 construct is delivered in vivo as is, as it is a
singular antigen fusion between the Hepatitis B surface antigen (HbsAg) and CSP. To
assemble a mimic of RTS,S we designed two constructs, one encoding HbsAg and a
second RTS construct. The final plasmids were mixed at a 1:4 ratio of RTS to HbsAg
(Figure 3.3A) to mimic its production as a final protein particle antigen190.
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Expression of each construct was studied by western blots of supernatants
collected from transfected cells, using the anti-CSP monoclonal antibody 311 for
detection. dR21 and dRTS,S both expressed in-vitro (Figure 3.3B). To elucidate whether
dR21 and dRTS,S were forming nanoparticles similarly to their protein formulation
counterparts, supernatants from transfected cells were run on a discontinuous sucrose
gradient and separated by molecular weight via ultracentrifugation for 24 hours. The
resulting gradient fractions were analyzed by western blot for CSP expression (Figure
3.3C). We observed protein bands with high molecular weight from supernatants
collected from both dRTS,S and dR21 transfected cells, that may correspond to higherorder structures such as polyvalent particles. We also observed CSP in high molecular
weight fractions of supernatants collected from ΔGPI transfected cells, suggesting that
this vaccine construct is also capable of forming multimeric aggregates similar to
dRTS,S and dR21. This phenomenon was not observed in supernatants collected from
3D7 transfected cells, and thus may be a contributing factor behind the superior
protection observed in Figure 3.2. To evaluate the biophysical properties of the high
molecular weight fractions which contained CSP (Figure 3.3C), we analyzed relevant
fractions with negative stain electron microscopy (nsEM). Higher-order structures
ranging in diameter from 20nm to 50nm were observed in the high molecular weight
fractions from dRTS,S, dR21, and ΔGPI transfected cells, and not in mock transfected
cells (Figure 3.3D).
Both dRTS,S and dR21 induced an potent IFNγ cellular response. Using
separate peptide pools for mapping we observed that the majority of the CSP response
to dRTS,S and dR21 was directed at the c-terminus region of CSP. Although the cellular
response does target CSP, majority of the vaccine-induced cellular response was
specific to HbsAg but not to CSP (Figure 3.4D). In contrast, immunization with ΔGPI only
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elicits an IFNγ response against the CSP protein, and at a higher magnitude than dR21
and dRTS,S (Figure 3.4C-D). However, this focusing of the cellular response onto the
carrier protein did not impair the antibody response, as immunization with both dRTS,S
and dR21 elicited robust anti-rCSP antibody titers. Comparison of the responses
demonstrated that immunization with ΔGPI resulted in slightly higher Ab responses
against recombinant CSP than dR21 and dRTS,S (Figure 3.4A). Neither ΔGPI nor dR21
elicited an anti-HBsAg antibody response, whereas dRTS,S did (Figure 3.4B). The
higher molar ratio of HBsAg in dRTS,S may be responsible for this observation,
however further study of these differences could generate additional insight.
Polyvalent CSP constructs elicit a robust Ab response and are protective against
a rigorous mosquito bite challenge model
ΔGPI, the most potent construct from the initial CSP DNA vaccine study and
challenge experiment, and the construct which demonstrated high-molecular weight
aggregate formation along with dRTS,S and R21, were evaluated in a more rigorous
mosquito bite malaria challenge model191. Groups of five BALB/c mice were immunized
with 25 µg of vaccine four times, three weeks apart (weeks 0,3,6,9). Three weeks after
the last immunization, the mice were challenged with Plasmodium berghei (Pb)
transgenic parasites which express the full-length Plasmodium falciparum
circumsporozoite protein (PfCSP), as well as luciferase as a reporter for liver parasite
load. This parasite is denoted from this point on as PbPfLuc. A cage of Anopheles
stephensi mosquitoes, 20 days after blood feeding on PbPfLuc infected mice was found
to be 90% infected with PbPfLuc. Based on this calculation that 90% of the mosquitos in
the cage were infected, 5 mosquitoes were required to challenge mice to ensure robust
infection by mosquito bites, as described192. Mice were anesthetized with 2% Avertin
prior to challenge. Mosquitoes were allowed to feed on the animals for ~10 minutes.
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After feeding, the number of mosquitoes positive for a blood meal were determined
(Figure 3.5A).
42 hours after challenge, mice were intraperitoneally injected with 100 μl of Dluciferin (30 mg/mL), anesthetized and liver luminescence was measured by using the
Perkin Elmer IVIS Spectrum Imaging System to assay liver parasite loads. Inhibition of
liver infection is expressed as a function of relative infection compared to naive mice.
Mice immunized with ΔGPI have the highest inhibition of liver infection observed in
vaccinated groups (84.6%), while the positive control, 100 ug of the MAb 311
demonstrates an 88.7% inhibition of liver stage infection in this model (Figure 3.5B-D).
dRTS,S and dR21 demonstrated overall potent protection of 81.5% and 82.6% inhibition
respectively (Figure 3.5B-D). Beginning on day 4 post-infection, blood smears were
taken to evaluate protection from blood stage parasitemia. All mice immunized with the
empty vector control, pVax, succumbed into blood stage infection by day 4. Of the five
mice immunized with dRTS,S, two mice developed blood stage parasitemia by day 5,
and a third on day 6. Of the five mice immunized with dR21, one developed blood stage
parasitemia at day 4, a total of three by day 5, and 4/5 mice had developed parasitemia
by day 6 post infection. Of the mice immunized with ΔGPI, one fell ill by day 4, and a
second by day 5, leaving 3/5 mice with sterile protection from blood stage parasitemia.
Finally, of the mice treated with 100 ug of the MAb 311 as a positive control, one
developed BS parasitemia by day 4, and a second developed BS parasitemia by day 8,
leaving 3/5 mice with sterile protection from blood stage parasitemia (Figure 3.5E) and
serves as a robust control. This is the first demonstration that genetically encoded
dRTS,S or dR21 can drive robust protection, similar to prior reports of these
immunogens as protein based vaccines. Furthermore, in the side by side comparison
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ΔGPI exhibited protection which was comparable to the genetically encoded dRTS,S
and dR21, as well as the monoclonal antibody positive control.
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Discussion
CSP has long been a focus in malaria vaccine research, and for good reason, as
anti-CSP antibodies are one of the predominant correlates of protection for malaria
infection187. CSP is composed of an N-terminal domain containing a conserved
proteolytic cleavage cite, a central repeat region, and a c-terminal domain173. CSP
undergoes significant conformational change during the parasite’s migration from the
mosquito salivary gland to the mammalian liver. When first entering the bloodstream,
CSP is in a folded conformation on the surface of the sporozoite. As the parasite
reaches the liver, CSP undergoes proteolytic cleavage, which has been shown to be a
critical requirement for hepatocyte invasion174. In addition it is known that antibody
binding to sporozoites abolish their motility193 and induces a cytotoxic effect194 that
neutralize their infectivity. Consequently, antibodies targeting CSP have the potential to
strongly inhibit sporozoite invasion of hepatocytes and can thus be protective against
disease195.
RTS,S is a recombinant protein-based vaccine comprised of a fragment of CSP
containing a section of the repeat region, and the T cell epitopes of the c-terminus
attached to the Hepatitis B surface antigen protein, and delivered with additional HbsAg
to encourage the formation of virus-like-particles in yeast, which are then harvested and
administered with an adjuvant to humans to generate a T cell and antibody response. In
contrast, while the R21 vaccine is also a recombinant protein-based vaccine, containing
the same NANP repeats and T cell epitopes of the C-terminus as RTS,S does, it is able
to form particles in yeast without additional HbsAg, meaning that a higher proportion of
antigen seen by the immune system will be Plasmodium antigen rather than Hepatitis B
antigen. RTS,S, when formulated with adjuvant, induces antigen-specific humoral and
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CD4 T cell cellular responses in BALB/c mice196 and in humans 197–200. R21, when
formulated with adjuvant or delivered with a TRAP-based viral vector prime-boost, also
demonstrated a robust humoral and cellular response69. Genetically encoded RTS,S and
R21 surrogates were highly immunogenic and protective in a rigorous malaria challenge
model and performed similarly to their protein counterparts69,196–199,201. However, the
majority of the IFNy response elicited by dRTS,S and dR21 was directed against the
HbsAg rather than against CSP. In contrast, our primary CSP candidate vaccine, ΔGPI,
elicited a cellular response to only CSP, not to HbsAg, thus the response appears more
focused towards the CSP antigen targeted by the vaccine.
This study demonstrates the potential for a synDNA vaccine targeting CSP to be
highly immunogenic and efficacious. I show that a synthetic DNA vaccine targeting the
circumsporozoite protein of Plasmodium falciparum can induce a high-titer anti-CSP
antibody response, as well as a robust cellular response producing IFNy in response to
stimulation with CSP antigen. This immunogenicity elicited by the ΔGPI CSP vaccine
resulted in protection from infection in multiple models of murine malaria, including an IV
sporozoite challenge, and a rigorous infected mosquito bite challenge. Additionally, this
study is the first to show that synDNA mimics of the leading CSP vaccine candidates
RTS,S and R21 generate strong humoral and cellular responses, resulting in protection
from infection in an infected mosquito bite challenge model.
Nanoparticle vaccines have become a focus in recent years. Nanoparticles,
ordered structures with dimensions in the range of 1-1000 nm, can function as both a
delivery system, and/or immune potentiators202,203. Nanoparticles which have a
comparable size to pathogens are taken up efficiently by APCs202. Further, the display of
antigen in a repetitive array mimics the surface of a pathogen (i.e. as CSP densely coats
the surface of sporozoites), and this allows for enhancement of innate immune
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activation, improved drainage and retention in the lymph node, stronger engagement
with B cell receptors, and consequently augmented T cell help to B cells203. Within the
context of prophylactic malaria vaccines, nanoparticle vaccines have been shown to
drive broader humoral responses, a balanced Th1/Th2 cytokine profile, and robust
germinal center formulation204. Malaria protein targeting nanoparticles have also been
shown to increase Ab titers, and increase antigen specific plasmablasts, circulating
memory B cells, and plasma cells in the bone marrow, as well as inducing antigen
specific circulating Tfh cells205. There is precedent for synDNA launched nanoparticle
vaccines spontaneously self-assembling in vivo, and driving stronger humoral responses
than monomeric DNA vaccines186.Thus I postulate that our synDNA vaccine mimics of
the nanoparticle forming RTS,S and R21 vaccines, as well as our novel synDNA vaccine
“ΔGPI”, all of which form high molecular weight aggreagtes which may be nanoparticles
in vitro, may promote enhanced trafficking to lymph nodes, robust germinal center
formation, and consequent increases in anti-CSP antibodies as compared to nonnanoparticle forming vaccines.
I believe this platform of in-vivo launched polyvalent nanoparticle vaccines
targeting CSP has the potential to deliver high level protection from malaria infection, in
a temperature stable and cost-effective manner which makes it particularly well suited to
use in low-resource settings.
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Materials and Methods
Cell lines and transfection
To probe for in vitro expression of the vaccine constructs, the Expi293F
transfection kit (ThermoFisher) was used for all transfections. Expi293F cells were
maintained in Expi293 Expression Medium for passages, and cells were incubated in 8%
CO2 conditions on an orbital shaker at 37°C. Briefly, one day prior to transfection, 2x105
Expi293F cells at 95% viability or greater were plated in Expression Medium. DNA
plasmids were added to Opti-MEM media separately from ExpiFectamine transfection
reagent. After a 5-minute incubation period, DNA and ExpiFectamine were complexed
during a 20-minute incubation period. Subsequently, the DNA plasmid complex was
added to Expi293F cells in suspension. Eighteen hours after the addition of DNA,
Transfection Enhancers were added according to manufacturer’s instructions. After three
to five days, cell supernatants and lysates were collected for further studies.
Western Blot
To detect vaccine construct expression in transfection supernatants and lysates,
12µL of sample was run on 4-12% Bis-Tris gel (ThermoFisher) in MES buffer. Samples
were boiled and reduced before being run. Upon completion of the gel, contents of the
gel were transferred to a nitrocellulose membrane via the iBlot 2 Transfer system
(ThermoFisher). Upon transfer completion, the membrane was blocked using Intercept
Blocking Buffer (LI-COR) for one hour at room temperature. After blocking, the
membranes were probed with the anti-CSP human MAb 311 at a 1:1000 dilution in
blocking buffer at 4°C overnight. The following day, a fluorescently labelled anti-human
secondary antibody was added to the membrane, formulated in Intercept Blocking
Buffer, SDS, PBS, and Tween-20 for a one-hour incubation. Following secondary
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incubation, the membrane was washed with PBS + 0.1%% Tween-20 four times, and
was subsequently imaged using the LI-COR Odyssey CLx.
Ultracentrifugation and gradient fraction collection
In order to assess the polyvalency and structural formation of vaccine constructs,
transfectant supernatants were collected and filtered through a 0.45micron filter to
remove cell debris. Then an Amicon Ultra-15mL 10k filter was used to concentrate 15
mL of sample with a 4,000x g spin for approximately 15-40 minutes. Concentrated
protein (1g) was loaded onto a 5ml 10-50% discontinuous sucrose gradient (50 mM Tris,
pH 8, 150 mM NaCl, 2 mM EDTA, 50 mM NaF, 5 mM sodium pyrophosphate, 10-50%
sucrose) and ultracentrifuged (39,800 rpm) for 24 hours at 4°C. Fractions (250 µL) were
collected and stored at -20°C.
Electron Microscopy
Fractions were collected from the density gradient analysis, and dialysed into
PBS overnight using Slide-A-Lyzer mini dialysis devices (ThermoFisher), before being
concentrated via an Amicon Ultra-0.5mL 10k filter. 3 µl of each sample was applied to a
thin carbon grid that was glow discharged for 30 seconds at 30 mAmps current using
pelco easyglow glow discharger. 3µl of freshly made solution of 2% uranyl acetate was
used to stain each sample twice on the grid with 1 min of incubation time. Excess stain
and sample were removed by carefully blotting the grid at the edge with a Whatman filter
and the grid was allowed to dry until imaged. TEM micrographs were collected using
Tecnai T12 TEM microscope operated at 100KeV and the images were recorded at 20x
mag on Gatan 4K CMOS camera.
ELISA
For binding detection of CSP in transfection supernatants as well as
quantification of serum antibody titers, MaxiSorp 96-well plates or half-area plates
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(ThermoFisher) were coated overnight with 1 µg/mL of recombinant CSP (courtesy of
MVI/PATH) at 4°C. The next day, each plate was washed with Phosphate Buffered
Saline + 0.01% Tween-20 (PBS-T) four times (4x). Plates were then blocked with 5%
milk in PBS for two hours at RT. Upon completion of blocking, plates were washed
again, and samples diluted in 1% newborn calf serum (NCS) in PBST were transferred
onto the plates for a two-hour incubation at RT. Following sample incubation, plates
were washed, and goat anti-mouse or anti-human heavy and light chain HRP conjugated
secondary was diluted to 1:10,000 and transferred onto plates for a one-hour incubation
at RT. After secondary incubation, plates were washed and developed using
SIGMAFAST™ OPD (Sigma-Aldrich) for 10 minutes and then stopped with sulfuric acid.
The Biotek Synergy 2 plate reader was used to read plates at 450 nm. Data were
exported to Microsoft Excel and analyzed using GraphPad PRISM 8.
Animal studies and immunizations
BALB/c mice were purchased from the Jackson Laboratory. Animal experiments
were conducted under protocol #201236 approved by the Wistar Institutional Animal
Care and Use Committee (IACUC). All animals were housed in the Wistar Institute
Animal Facility, with the exception of challenge studies, which were performed at the
Johns Hopkins Bloomberg School of Public Health. Mice were immunized with 25µg of
DNA in sterile water intramuscularly in the tibialis anterior (TA) muscle and subsequently
electroporated using the CELLECTRA 3P adaptive electroporation device (Inovio
Pharmaceuticals). Mice were immunized four times, three weeks apart for all
experiments, including the challenge experiments. One week following each vaccination,
blood was collected via submandibular bleed to isolate sera for future experiments. In
addition, one week after the final immunization, mice were euthanized for splenocyte
collection for subsequent assays.
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Sample processing and ELISpot
Following euthanasia, spleens were harvested and temporarily stored in R10,
consisting of 10% FBS and 1% penicillin-streptomycin in RPMI 1640 (Invitrogen). Using
the Stomacher 80 tissue stomacher, spleens were homogenized for one minute before
filtering through a 40µm strainer. The cell mixture was centrifuged for 10 min at 1200
rpm and subsequently resuspended in ACK lysis buffer (Gibco) for a 5 minute period.
Cells were washed with PBS prior to centrifugation and resuspension in 20mL R10
media for counting on a COUNTESS II (Invitrogen).
To assess antigen specific interferon gamma (IFNγ) production, mouse IFNγ
ELISpot PLUS (Mabtech) plates were used according to the protocol provided by the
manufacturer. Briefly, plates were washed using sterile PBS followed by blocking with
200µL per well of R10. Plates were seeded with 200,000 cells in 100µL R10 in triplicate.
Cells were stimulated with peptide pools of 15mers overlapping by 11 amino acids
spanning the entire vaccine antigen at a final concentration of 5 μg/mL per peptide. R10
and Concanavalin A were used as negative and positive controls, respectively. After an
18-hour incubation in 5% CO2 conditions at 37°C, plates were developed according to
the protocol provided by the manufacturer. After developing, the CTL ImmunoSpot S6
Universal Analyzer (Cellular Technology Limited) was used to scan and count plates.
Data analysis was performed using GraphPad PRISM 8.
IV sporozoite challenge
Challenge study was performed at Johns Hopkins under IACUC #MO16H35.
Each mouse was immunized via intramuscular injection followed by electroporation on
weeks 0, 3, 6 and 9. On week 11 of the experiment, mice were challenged with
Plasmodium berghei (Pb) transgenic parasites that express the full-length Plasmodium
falciparum circumsporozoite protein (PfCSP), as well as luciferase to report liver parasite
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load as described192. This parasite is denoted from this point on as PbPfLuc. Briefly, the
311-100 μg cohort was injected with 100 μg of human mAb 311 16 hours prior to
challenge, and age-matched all other mice; this cohort served as a control for protection.
42 hours after intravenous injection of 250 sporozoites, mice were intraperitoneally
injected with 100 μl of D-luciferin (30 mg/mL), anesthetized and liver luminescence was
measured with the Perkin Elmer IVIS Spectrum Imaging System to assay liver loads.
Mann Whitney tests were used to compare luminescence between immunized groups
and the naïve control.
Infectious mosquito bite challenge
Challenge study was performed at Johns Hopkins under IACUC #MO16H35.
Each mouse was immunized via intramuscular injection followed by electroporation on
weeks 0, 3, 6 and 9. Serum was isolated from each mouse via retro orbital bleeding 3
days prior to challenge. The 311-100 μg cohort was injected with 100 μg of human mAb
311 16 hours prior to challenge, and age-matched all other mice; this cohort served as a
control for protection. On week 12 of the experiment, mice were challenged with
PbPfLuc via infectious mosquito bite. A cage of Anopheles stephensi mosquitoes, 20
days after blood feeding on PbPfLuc infected mice was determined to be 90% infected
with PbPfLuc. Based on this calculation, it was determined that 5 mosquitoes were
needed to challenge mice with infected mosquito bites, as described192. Briefly, mice
were anesthetized with 2% Avertin prior to challenge. Mosquitoes were allowed to feed
on mice for ~10 minutes. After feeding, the number of mosquitoes positive for a blood
meal was determined. 42 hours after mosquito bite challenge, liver parasite load was
measured using the Perkin Elmer IVIS Spectrum Imaging System. Mice were injected
with 100µl of D-Luciferin (30mg/mL), anesthetized with isoflurane and imaged with the
IVIS Spectrum to measure bioluminescence expressed by the transgenic parasites.
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Mann Whitney tests were used to compare luminescence between immunized groups
and the naïve control. Blood smears were taken beginning on day 4 post-infection to
evaluate parasitemia. A positive result was considered an endpoint. Mice were
euthanized upon confirmation of blood stage parasitemia.
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Figures

Figure 3.1 DNA vaccine construct design and in vitro expression. (A) Schematic diagram of
Plasmodium falciparum (Pf) gene inserts used to generate the codon-optimized DNA vaccine
constructs. The schematic details leader sequence (IgE) and gene insert. *This does not
represent the true structure of CSP, and is merely a graphic (B) in-vitro expression of vaccine
constructs in 293T cells via western blot, anti-CSP monoclonal Ab MAb 311 used as probe.
(C) quantified CSP signal from (B)
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Figure 3.2: synDNA CSP vaccine constructs elicit a robust immune response and are
protective against IV sporozoite Pf challenge
(A) Experiment layout. Mice were immunized four times, three weeks apart, and challenged
with 250 sporozoites IV three weeks after the last immunization. Sera was collected prior to
challenge for Ab analysis. Liver parasite burden was measured by IVIS. In a separate
experiment mice received the same treatment, and splenocytes were harvested for immune
cell analysis as in panel D. (B-C) ELISA’s of pooled sera for each cohort. Panel B tested sera
against recombinant CSP, while panel C tested sera against the NANP peptide. Sera was
initially diluted 1:200, and 3-fold serial dilutions were made afterwards. Monoclonal
antibody 2A10 was used as a positive control. (D) The Pf CSP antigen-specific cellular
immune response induced by the indicated DNA vaccine measured by IFNγ ELISPOT. Cells
were stimulated for 18 hr with peptide pools encompassing the entire protein. (E) Graphical
representation of luminescence data. Bar graph of mean luminescence for each group, and
results of Mann Whitney tests comparing groups to Naive Infected. Both AB311 and dGPI
demonstrate statistically significant differences compared to Naive Infected (**:P < 0.05). (F)
Inhibition of liver infection as expressed as a function of relative infection compared to naive
mice. Mice immunized with dGPI have the highest inhibition of liver infection (64.17%),
while 311 treatment demonstrates an 80% inhibition of liver stage infection. (G)
Representative IVIS images for each experimental group
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Figure 3.3: The development of benchmark CSP control vaccines. (A) Schematic diagram of
gene inserts used to generate the DNA vaccine constructs. The schematic details leader
sequence (IgE) and gene insert, as well as ratio of delivery. (B) western blot of construct
expression, supernatants from transfected 293T cells were probed with the MAb 311 (antiCSP) (C) Discontinuous sucrose gradient fractions probed for CSP. The high molecular weight
fractions denoted in red boxes were combined and imagined by negative staining electron
microscopy as shown in (D). (D) Particle formation of vaccines in vitro. Examples of particles
are encircled (not exhaustive, i.e. not all particles are circled).
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Figure 3.4: synDNA CSP constructs elicit a robust response. Mice were immunized four
times, three weeks apart. Sera and splenocytes were collected three weeks after the last
immunization for immune analysis. (A) ELISAs to assess rCSP binding by Ab elicited after final
vaccination. (B) ELISAs to assess HBsAg binding by Ab elicited after final vaccination (C) The
Pf CSP antigen-specific cellular immune response induced by the indicated DNA vaccine
measured by IFNγ ELISPOT. Cells were stimulated for 18 hr with peptide pools encompassing
the entire protein. (D) The HBsAg specific cellular immune response induced by the indicated
DNA vaccine measured by IFNγ ELISPOT. Cells were stimulated for 18 hr with peptide pools
encompassing the entire protein.
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Figure 3.5: synDNA CSP constructs are protective in challenge. (A) Experimental layout:
Mice were immunized four times, three weeks apart, and challenged three weeks after the
last immunization by infected mosquito bite. Liver parasite burden was assessed by IVIS.
Blood parasite burden was assessed by daily blood smears. (B) Graphical representation of
luminescence data. Bars indicate the mean and standard deviations. Bar graph of means and
results of Mann Whitney tests comparing groups to Naive Infected. (C) Inhibition of liver
infection as expressed as a function of relative infection compared to naive mice. (D)
representative IVIS images from each group (E) %blood stage parasite free mice, as assessed
by blood smears each day post challenge.
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CHAPTER 4: Discussion and Conclusions

4.1 Strategic interruption of the Plasmodium life cycle
As discussed in chapter 1, understanding the Plasmodium lifecycle and its points
of weakness is crucial to developing effective interventions. The Plasmodium lifecycle
has several “bottleneck” steps which make enticing vaccine targets. One of these socalled bottlenecks is the invasion of hepatocytes by sporozoites. Although many
sporozoites are injected in the saliva of the mosquito vector, the majority of them die in
the dermis and never migrate to the liver. While the number of sporozoites which leave
the dermis and migrate to the liver is small, if even one sporozoite manages to evade
immune detection and removal, schizogony in the liver will result in tens of thousands of
merozoites to cause the symptomatic blood infection. If the goal of a prophylactic
malaria vaccine is the same as most prophylactic vaccines- that is, to prevent
symptomatic disease, then it is clear that our focus should be on a pre-erythrocytic
vaccine. Two strategies of pre-erythrocytic vaccines are (1) to prevent the sporozoites
from successfully invading hepatocytes and (2) to kill infected hepatocytes before
merozoite development is complete (Figure 4.1).
In chapter 2 I focused on the second strategy, cell mediated immunity targeting
the liver stage of infection. The studies in this chapter built off of previous work in the
field of malaria vaccinology which highlighted the importance of both CD4+ and CD8+ T
cells in anti-malaria immunity, namely studies by Steven Hoffman’s206–208 and Stephan
Kappe’s66,84,153 groups on irradiated and genetically attenuated sporozoites, respectively.
I showed that a synDNA vaccine targeting liver stage Plasmodium antigens can drive an
antigen specific liver localized T cell population. I demonstrated through T cell assays
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including ELISpots and Flow Cytometry that synDNA vaccination with EXP1, PFN,
EXP2, ICP, UIS3, and TMP21, in combination or alone, elicits a robust T cell response,
as well as the production of antibodies against these peptides. This T cell response was
consequential, and resulted in 70-88% protection from blood-stage disease in an IV
sporozoite challenge model of murine malaria infection. The use of the molecular
adjuvant pIL-33 increased the immune response to vaccine and results in 100%
protection from blood stage disease after sporozoite challenge. I hypothesize that this
increase in protective efficacy in the adjuvanted groups is related to the increase in in
antigen responsive liver associated T cells, as well as their polyfunctionality as
demonstrated by enhanced cytokine poly-positivity in adjuvanted groups, though this
hypothesis should be investigated further to elucidate mechanism in more detail.
Altogether, the data suggest cell-mediated immunity against this obligate intracellular
stage of the pathogen should be considered when designing anti-malarial vaccines, and
support the continued examination of liver stage antigens as components of a
prophylactic vaccine. Additional focus on LS antigens as a component of a malaria
vaccine is warranted, potentially in combination with sporozoite antigens such as CSP.
In chapter 3 I focused on the first strategy of pre-erythrocytic vaccines,
prevention of sporozoite invasion and establishment of liver infection. This work was
largely inspired by the RTS,S vaccine studies which implicated antibodies against CSP
as a key correlate of protection180,197,200,201. In these studies, I showed that a synDNA
vaccine targeting the circumsporozoite protein of Plasmodium falciparum can induce a
high-titer anti-CSP antibody response, as well as a robust cellular response producing
IFNy in response to stimulation with CSP antigen. This immunogenicity elicited by the
ΔGPI CSP vaccine resulted in protection from infection in multiple models of murine
77

malaria, including an IV sporozoite challenge, and a rigorous infected mosquito bite
challenge. Additionally, this study is the first to show that synDNA mimics of the leading
CSP vaccine candidates RTS,S and R21 generate strong humoral and cellular
responses, resulting in protection from infection in an infected mosquito bite challenge
model. However, the majority of the IFNy response elicited by dRTS,S and dR21 was
directed against the HbsAg rather than against CSP. In contrast, our primary CSP
candidate vaccine, ΔGPI, elicited a cellular response to only CSP, not to HbsAg, thus
the response appears more focused towards the CSP antigen targeted by the vaccine. It
would be interesting to compare the original protein and adjuvant formulations of RTS,S
and R21 against the synDNA mimics we developed, as well as against our own novel
anti-CSP vaccine ΔGPI. It is possible that the synDNA platform would offer a novel and
potentially more immunogenic method of delivery for vaccine antigens such as CSP. I
believe this platform of DNA encoded, in-vivo launched vaccines targeting CSP has the
potential to deliver high level protection from malaria infection, in a temperature stable
and cost-effective manner which makes it particularly well suited to use in low-resource
settings.
In both of these series of studies, I demonstrated the efficacy of targeting the preerythrocytic stages of infection for prevention of disease. I found that targeting either of
the pre-erythrocytic stages, sporozoites or liver stage, elicited robust immunity to malaria
infection in a murine challenge model. I consequently hypothesize that a multi-valent
vaccine which targets both pre-erythrocytic stages of infection may exhibit synergistic
effects.
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4.2 The next generation of malaria vaccines: emphasis on multivalency and
advanced platforms
Prior vaccine studies suggest that a mono-antigen vaccine will be of limited use
in preventing a disease with such a varied antigenicity and multiple strains. Monoantigenic vaccines, notably RTS,S, have had limited success. The fact that the most
robust protection is elicited by attenuated sporozoites is indicative of the need for a
vaccine which targets many antigens and potentially multiple lifecycle stages. The next
generation of malaria vaccines will need to be cognizant of this. The field of malaria
vaccine development has been plagued by several challenges. The first is the
questionable usefulness of the murine models which are widely used209. Even within a
single species of Plasmodium, there is wide antigenic variability between strains, and the
variability between species is even higher. Because of this, many groups have begun
testing their novel vaccines in controlled human malaria infections (CHMI), in which
naïve western volunteers are vaccinated and subsequently challenged with a single
strain of Plasmodium falciparum210. However, even this model of malaria infection has
significant constraints, as vaccines which perform remarkably well in CHMI trials
(RTS,S211, irradiated sporozoites212) struggled when deployed in areas of endemic
infection. One potential cause of this dissonance is the interference of natural immunity
with vaccine elicited immunity. It has been shown that non neutralizing antibodies
against the sporozoite can abrogate protection from neutralizing antibodies, which may
be a mechanism through which Plasmodium evades vaccine immunity213. Unfortunately,
unlike immunity to many viral infections, natural immunity to malaria infection has not
been a fount of wisdom to inform vaccine design. As discussed in chapter 1.3, natural
immunity to malaria is strain-specific, built up slowly over time, and wanes quickly. We
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must continue to toil to understand natural immunity to malaria, and if we cannot mimic it
to design effective vaccines, we must understand how to work with it rather than against
it, OR how to avoid the potential inhibitory effects of natural immunity on vaccine elicited
immunity.
The next generation of malaria vaccines must be able to elicit durable, crossstrain protection. Some of the answer to this dilemma lies in the choice of antigen or
antigens included in the vaccine, and some lies in the choice of vaccine platform. I argue
that the ideal malaria vaccine will include antigens from multiple life cycle stages, both
pre-erythrocytic and erythrocytic. Including pre-erythrocytic antigens will aim to prevent
the infection from reaching the symptomatic blood stage, and including erythrocytic
antigens will aim to mitigate the symptoms in the case of breakthrough infection. The
inclusion of a transmission blocking antigen, as discussed in chapter 1.4, may also be a
valuable addition to the malaria elimination arsenal. In addition to antigen selection,
vaccine platform will also be of importance. As covered in chapter 1.5, the 1st and 2nd
generation vaccine platforms, while formidable and hugely important in eradicating,
eliminating, or greatly decreasing many pathogens of importance for human and animal
health, have historically struggled to elicited the CD8+ T cell mediated immunity needed
to control pathogens with an obligate intracellular stage of infection. Novel vaccine
platforms, such as nucleic acid vaccines and nanoparticle vaccines, will be able to
address this gap in vaccine elicited immunity in future vaccination endeavors.

4.3 Concluding remarks
Although I strongly believe in the power of vaccines to control infectious
diseases, it is unlikely that any one prophylactic malaria vaccine will be a silver bullet.
Rather, a prophylactic malaria vaccine like RTS,S or one of the nucleic acid vaccine
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strategies described above are an important part of the global health community’s
arsenal in combatting one of humanity’s most ancient foes. Other aspects of this arsenal
include novel therapeutics, continued vigilance against drug resistant parasites and
pesticide resistant mosquitoes, and the continued use of bed nets and other such
avoidance techniques. The WHO Global Technical Strategy for Malaria 2016-2030
established the goals of 1) reducing malaria case incidence by 90% by 2030, 2) reducing
malaria mortality by at least 90%, and 3) eliminating malaria in at least 35 countries27.
Through a coordinated, interdisciplinary effort between immunologists, parasitologists,
vaccinologists, epidemiologists and others we can look to a future where these goals
have been realized. Eventually, though perhaps not by 2030, I believe the combined
efforts of generations of scientists, doctors, and public health officials will culminate in a
world free of malaria.
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Figure 4.1: Strategic interruption of the Plasmodium life cycle. Life cycle stages to be
targeted by vaccines to prevent symptomatic infection shown in boxes. Figure generated
with BioRender©
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